Potency enhancing sequences for subcutaneously administrated gene therapies

Optimized regulatory and polyadenylation sequences in gene therapy constructs for subcutaneous administration address transgene expression inefficiencies and size-related reductions, enhancing potency and safety in adipocyte-targeted gene therapies.

WO2026241467A1PCT designated stage Publication Date: 2026-11-19REMEDIUM BIO INC +6
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028101
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Systemically administered gene therapies often localize to the liver and spleen, leading to toxicity, immunogenicity, and antigenicity, while subcutaneous administration faces challenges with transgene expression efficiency due to differences in cellular machinery between hepatocytes and adipocytes, and non-viral vectors face potency reductions with increased genetic cassette size.

Method used

Incorporation of specific regulatory sequences and polyadenylation sequences in gene therapy constructs for subcutaneous administration, optimized for adipocyte localization, to enhance expression and overcome size-dependent reductions.

Benefits of technology

The constructs achieve enhanced expression and localized delivery of therapeutic proteins, improving safety and tolerability by maintaining expression levels and reducing systemic exposure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028101_19112026_PF_FP_ABST
    Figure US2026028101_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides, at least in part, potency enhancing sequences for subcutaneously administered gene therapies and their application for subcutaneous delivery of genetic medicine, such as using viral and non-viral vectors. Related compositions and methods are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] R0872.70015WG00

[0002] POTENCY ENHANCING SEQUENCES FOR SUBCUTANEOUSLY ADMINISTRATED GENE THERAPIES

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No.

[0005] 63 / 805,211, filed May 13, 2025, entitled “POTENCY ENHANCING SEQUENCES FOR SUBCUTANEOUSLY ADMINISTRATED GENE THERAPIES”, the entire disclosure of which is hereby incorporated by reference in its entirety.

[0006] REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0007] The contents of the electronic sequence listing (R087270015WO00-SEQ-JAV.xml; Size: 144,649 bytes; and Date of Creation: May 12, 2026) are herein incorporated by references in their entirety.

[0008] FIELD OF THE INVENTION

[0009] The present invention provides, at least in part, potency enhancing sequences for subcutaneously administered gene therapies and their application for subcutaneous delivery of genetic medicine, such as using viral and non-viral vectors. Related compositions and methods are also provided.

[0010] BACKGROUND OF THE INVENTION

[0011] Gene therapy treatments offer significant therapeutic potential for a broad range of pathologies. Over the last decade, gene therapy has emerged as a transformative therapeutic modality for a wide spectrum of diseases by enabling sustained expression of therapeutic proteins through the introduction of exogenous genetic material. The route of administration for gene therapies has been either local, or directly to the target tissues, such as in the case of subretinally delivered gene therapies, or systemic, delivered intravenously. Systemically administered gene therapies have demonstrated a strong tendency to localize to filtration organs such as the liver and spleen. While this biodistribution is advantageous in some cases, particularly for liver-targeted diseases, it also carries with it a number of significant drawbacks. These drawbacks include heightened risk of off-target toxicity, immune responses to the vector or transgene product, and challenges related to

[0012] #15259787vlantigenicity, particularly in the context of repeated dosing or long-term expression. Finally, the liver, and more specifically hepatocytes are life- and function-sustaining tissues / cells, and the localization resulting vector related toxicity can not only limit the initial treatment, but prevent downstream down-titration post treatment.

[0013] SUMMARY OF THE INVENTION

[0014] Systemically administered treatments ostensibly localize to the liver and spleen and are associated with significant risks of toxicity, immunogenicity, and antigenicity. Subcutaneously administered gene therapies offer a novel means to deliver genetic material to predominantly non-life- / non-function-sustaining tissues, and when coupled with adipocyte targeting or subcutaneous localization factors, the DNA can remain relatively local to the subcutaneous area of injection, while the produced and secreted therapeutic protein can be biodistributed systemically to mediate its intended effect. However, potency enhancing factors for subcutaneously delivered gene therapies are generally not known, especially such factors that are related to genetic enhancers and regulators, which are particularly important such as for non-virally delivered DNA, which are known to have an inverse proportion between the size of the delivered genetic cassette and its potency.

[0015] Subcutaneous administration of gene therapies offers an alternative route with the potential to mitigate many of these limitations. In this approach, DNA can be delivered via viral or non-viral vectors directly into the subcutaneous space, enabling more localized expression and potentially limiting exposure to sensitive systemic tissues. Moreover, when combined with targeting elements aimed at localizing the therapeutic transgene to adipocytes or other resident subcutaneous cells, the delivered transgene can remain localized to the injection site while still allowing systemically distributed therapeutic proteins to exert their effects throughout the body following production, secretion, and biodistribution.

[0016] Despite its promise, the subcutaneous route presents challenges, especially with respect to transgene expression efficiency. One key issue is that many of the genetic regulatory elements — such as promoters, enhancers, and untranslated regions — used in conventional gene therapy constructs have been optimized primarily for hepatocytes, due to the liver’s dominant role in

[0017] #15259787vlsystemic gene expression following intravenous administration. However, hepatocytes and adipocytes, or generally resident cells of the subcutis differ significantly in their cellular machinery, including their transcription factor profiles, chromatin accessibility, proteomes, and expressomes. As a result, enhancers and regulators that are highly active in hepatocytes may be suboptimally active, or entirely ineffective, in subcutaneous cell types.

[0018] This tissue-specific variability underscores the need for the identification and optimization of genetic regulatory sequences that are specifically tailored to enhance gene expression in subcutaneous tissue. Such regulatory elements generally should be compatible with the transcriptional landscape of cells like adipocytes or other resident cells of the subcutis, which differ markedly from hepatic cells in both their basal and inducible gene expression programs. Additionally, in the case of non-viral vectors — where the size of the genetic cassette inversely affects potency, the efficiency of expression can become even more reliant on the inclusion of compact, high-activity enhancers and other regulatory elements. Alternatively, enhancers or regulators that promote potency in excess of the reduction in expression as a result of the additional size are valuable particularly in non-virally delivered gene therapy treatments, for example. The present invention addresses these challenges by providing genetic enhancer elements and regulatory sequences that can improve the potency of gene expression following subcutaneous administration. These elements are designed to function effectively in subcutaneous tissues, either alone or in conjunction with tissue-targeting strategies, and are applicable across both viral and non-viral gene therapy platforms. Compositions and methods related to these elements and sequences are provided.

[0019] In one aspect, a gene therapy construct comprising (a) a nucleic acid encoding a therapeutic protein or peptide; (b) at least one regulatory sequence operably linked to the nucleic acid; and (c) at least one polyadenylation sequence operably linked to the regulatory sequence is provided. In one embodiment of any one of the compositions or methods provided herein, the polyadenylation sequence increases expression in subcutaneous tissue relative to a reference poly adenylation sequence.

[0020] #15259787vlIn one embodiment of any one of the compositions or methods provided herein, the gene therapy construct comprises a therapeutic genetic cassette having a total length of between 2208 nucleotides and 7356 nucleotides.

[0021] In one embodiment of any one of the compositions or methods provided herein, the gene therapy construct is configured for subcutaneous administration using a non-viral delivery vector.

[0022] In one embodiment of any one of the compositions or methods provided herein, inclusion of the regulatory sequence and the polyadenylation sequence results in an increase in expression of the therapeutic protein or peptide in vivo following subcutaneous administration relative to an otherwise identical construct lacking the regulatory sequence.

[0023] In one embodiment of any one of the compositions or methods provided herein, the increase in expression is greater than that achieved by inclusion of either the regulatory sequence alone or the polyadenylation sequence alone.

[0024] In one embodiment of any one of the compositions or methods provided herein, the increase in expression exceeds any reduction in expression attributable to an increase in construct size resulting from inclusion of the regulatory sequence and the polyadenylation sequence.

[0025] In one aspect, a method of treating a subject in need thereof, comprising subcutaneously administering to the subject any one of the gene therapy constructs provided herein is provided. In one embodiment of any one of the compositions or methods provided herein, the construct expresses a therapeutically effective amount of a therapeutic protein or peptide.

[0026] In one aspect, a use of a regulatory sequence and a polyadenylation sequence in combination to increase expression of a nucleic acid encoding a therapeutic protein or peptide following subcutaneous administration of a non-viral gene therapy construct is provided. In one embodiment of any one of the compositions or methods provided herein, the increase in expression exceeds any reduction attributable to an increase in construct size.

[0027] In one embodiment of any one of the compositions or methods provided herein, the non-viral delivery vector comprises a lipid nanoparticle.

[0028] #15259787vlIn one embodiment of any one of the compositions or methods provided herein, the construct is delivered without a viral capsid.

[0029] In one embodiment of any one of the compositions or methods provided herein, expression occurs in subcutaneous tissue. In one embodiment of any one of the compositions or methods provided herein, expression occurs in adipocytes.

[0030] In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence is positioned within 0 to 50 nucleotides downstream of a stop codon of the nucleic acid. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence is positioned within 0 to 12 nucleotides downstream of the stop codon. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence is positioned between 300 and 500 nucleotides downstream of a stop codon. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence is positioned between 350 and 420 nucleotides downstream of the stop codon.

[0031] In one embodiment of any one of the compositions or methods provided herein, further comprising a spacer sequence between the nucleic acid and the regulatory sequence. In one embodiment of any one of the compositions or methods provided herein, the spacer sequence comprises 0 to 12 nucleotides. In one embodiment of any one of the compositions or methods provided herein, the spacer comprises 1 to 3 nucleotides.

[0032] In one embodiment of any one of the compositions or methods provided herein, the increase in expression is at least 1.5-fold relative to the construct lacking the regulatory sequence. In one embodiment of any one of the compositions or methods provided herein, the increase in expression is at least 2-fold. In one embodiment of any one of the compositions or methods provided herein, the increase in expression is observed across constructs having lengths spanning 2208 to 7356 nucleotides.

[0033] In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises any one of the regulatory sequences provided herein. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises a nucleic acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: Reg 1-

[0034] #15259787vlReg 110. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence has at least 88% identity.

[0035] In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises a conserved motif derived from alignment of SEQ ID NOs: Reg 1-Reg 3. In one embodiment of any one of the compositions or methods provided herein, the polyadenylation sequence comprises any one of the polyadenylation sequences provided herein. In one embodiment of any one of the compositions or methods provided herein, the polyadenylation sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: pA 1-pA 53. In one embodiment of any one of the compositions or methods provided herein, the polyadenylation sequence has at least 88% identity.

[0036] In one embodiment of any one of the compositions or methods provided herein, the polyadenylation sequence comprises a consensus motif associated with increased expression in subcutaneous tissue.

[0037] In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises SEQ ID NO: Reg 1 and the polyadenylation sequence comprises SEQ ID NO: pA 4. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises SEQ ID NO: Reg 1 and the polyadenylation sequence comprises SEQ ID NO: pA 1. In one embodiment of any one of the compositions or methods provided herein, the regulatory sequence comprises SEQ ID NO: Reg 3 and the polyadenylation sequence comprises SEQ ID NO: pA 4.

[0038] In one embodiment of any one of the compositions or methods provided herein, the gene therapy construct does not comprise a sequence having at least 80% identity to SEQ ID NO: EE3.

[0039] In one embodiment of any one of the compositions or methods provided herein, the therapeutic protein or peptide is any one of the therapeutic proteins or peptides provided herein. In one embodiment of any one of the compositions or methods provided herein, the therapeutic protein or peptide is a secreted protein. In one embodiment of any one of the compositions or methods provided herein, the protein is a peptide hormone. In one embodiment of any one of the compositions or methods provided herein, the protein is an antibody or antibody fragment.

[0040] #15259787vlIn one aspect, a gene therapy construct comprising a nucleic acid encoding a therapeutic protein, a regulatory sequence selected from SEQ ID NOs: Reg 1-Reg 110, and a polyadenylation sequence selected from SEQ ID NOs: pA 1-pA 53 is provided. In one embodiment of any one of the compositions or methods provided herein, the construct increases expression following subcutaneous administration relative to a construct lacking the regulatory sequence.

[0041] In one aspect is any one of the gene therapy constructs provided herein, a composition comprising any one of the gene therapy constructs provided herein or a method of administering any one of the gene therapy constructs provided herein to a subject.

[0042] In one aspect is a method of administering any one of the compositions or provided herein to a subject. In one embodiment, the subject may be any one of the subjects provided herein. In one embodiment, the administering may be via any mode of administration provided herein. In one embodiment, the administering may for any purpose provided herein.

[0043] In one aspect is any composition or method provided in the Examples.

[0044] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 demonstrates the distribution of certain proteomics and transcriptomics across cell types.

[0045] FIG. 2 shows the effect of the insertion of non-functional DNA blocks into non-viral delivery vector cassettes.

[0046] FIG. 3 shows the effect of Element 2 on total flux at one month.

[0047] FIG. 4 shows the effect of Element 3 on total flux at one month.

[0048] FIG. 5 shows a sequence alignment of top three performing regulatory sequences.

[0049] FIG. 6 shows the effect of pA consensus sequences on total flux at one month.

[0050] FIG. 7 shows a sequence alignment of top three performing regulatory sequences.

[0051] FIG. 8 shows an alignment for derivation of consensus sequences without the user of the optimized pA 5 sequence.

[0052] #15259787vlFIG. 9 shows the effect of enhancer use with pA3 on total flux at one month.

[0053] FIG. 10 shows the effect of general enhancer addition.

[0054] FIG. 11 shows the combinatorial effect of various regulatory enhancer elements and pA sequences.

[0055] FIG. 12 shows results from Example 6.

[0056] FIG. 13 shows results from Example 7.

[0057] FIG. 14 shows flux versus construct size (Example 8).

[0058] FIG. 15 shows total flux versus construct size (Example 8).

[0059] FIG. 16 shows SQ / body versus construct size (Example 8).

[0060] FIG. 17 shows SQ / body versus construct size (Example 8).

[0061] DETAILED DESCRIPTION OF INVENTION

[0062] Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified materials or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting of the use of alternative terminology to describe the present invention.

[0063] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety for all purposes. Such incorporation by reference is not intended to be an admission that any of the incorporated publications, patents and patent applications cited herein constitute prior art.

[0064] As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a molecule" includes a mixture of two or more such molecules or a plurality of such molecules, and the like.

[0065] As used herein, the term “comprise” or variations thereof such as “comprises” or “comprising” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element,

[0066] #15259787vlcharacteristic, property, method / process step or limitation) or group of integers (e.g. features, elements, characteristics, properties, method / process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein, the term “comprising” is inclusive and does not exclude additional, unrecited integers or method / process steps.

[0067] In embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of’ or “consisting of’. The phrase “consisting essentially of’ is used herein to require the specified integer(s) or steps as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the recited integer (e.g. a feature, element, characteristic, property, method / process step or limitation) or group of integers (e.g. features, elements, characteristics, properties, method / process steps or limitations) alone.

[0068] Summary

[0069] The present invention relates, at least in part, to gene therapy constructs configured for subcutaneous administration using non- viral delivery systems, wherein the constructs comprise a specific regulatory sequence and polyadenylation sequence architecture that enables enhanced expression of a therapeutic protein or peptide.

[0070] The invention is based, at least in part, on the discovery that expression from non-viral gene therapy constructs delivered subcutaneously is strongly dependent on genetic cassette size, and that this limitation can be overcome through the use of specific combinations of regulatory sequences and poly adenylation sequences.

[0071] In one aspect, the invention provides a gene therapy construct comprising:

[0072] • a nucleic acid encoding a therapeutic protein or peptide;

[0073] • at least one regulatory sequence operably linked to the nucleic acid; and

[0074] • at least one polyadenylation sequence operably linked to the regulatory sequence.

[0075] The regulatory sequence and poly adenylation sequence may be arranged in a 3' configuration relative to the coding sequence, optionally separated by a spacer sequence.

[0076] #15259787vlIn certain embodiments, the construct comprises a double-stranded circular DNA cassette, including nanoplasmid, minicircle, or generally fully or partially double stranded circular or linear DNA constructs.

[0077] The gene therapy construct may generally comprise a therapeutic genetic cassette having a total length between approximately 2208 nucleotides and 7356 nucleotides. This size range reflects the constraints of non- viral delivery systems, including lipid nanoparticle (LNP)-based delivery, where increases in construct size are associated with reduced delivery efficiency and expression. The constructs may be configured for subcutaneous administration, and may be delivered using non-viral vectors, including lipid nanoparticles, or in the absence of a viral capsid.

[0078] To evaluate the effect of construct size independent of functional regulatory activity, nonfunctional spacer sequences were used, and which sequences are defined as nucleic acid sequences that:

[0079] • do not contain promoter elements,

[0080] • do not contain transcriptional enhancers,

[0081] • do not contain post-transcriptional regulatory elements,

[0082] • do not contain polyadenylation signals, and

[0083] • are not known to increase gene expression.

[0084] As used herein, ‘non-functional spacer sequences’ refer to nucleic acid sequences that do not contain known transcriptional enhancers, promoters, post-transcriptional regulatory elements, polyadenylation signals, or motifs associated with increased gene expression.

[0085] These spacer sequences were used to systematically increase construct size without introducing functional activity.

[0086] A series of constructs were generated comprising identical coding sequences, promoters, and baseline polyadenylation elements, differing only in total cassette size due to the inclusion of non-functional spacer sequences.

[0087] Construct size was varied from approximately 2208 nucleotides to 7356 nucleotides using:

[0088] #15259787vl• external spacers, inserted downstream of the polyadenylation sequence; and • internal spacers, inserted upstream of the polyadenylation sequence and downstream of the coding sequence.

[0089] Across both configurations, expression decreased substantially as a function of increasing cassette size.

[0090] Expression levels decreased from approximately:

[0091] • 1 x 109photons / second (p / s) at -2208 nt,

[0092] to

[0093] • approximately 8 x 105photons / second (p / s) at -7300 nt.

[0094] This effect was independent of spacer position, demonstrating that the reduction in expression is driven by overall construct size, rather than sequence placement.

[0095] The relationship between construct size and expression defines a predictable regression curve, wherein increasing cassette size results in reduced expression output. This regression establishes a baseline expectation for expression levels in constructs lacking functional regulatory enhancement.

[0096] Polyadenylation sequences used in the present invention are generally and preferable subcutaneously functional, meaning that they can increase expression following subcutaneous administration relative to a reference polyadenylation sequence under otherwise identical conditions. Such poly adenylation sequences may be selected from SEQ ID NOs: pA 1-pA 53, or variants thereof having at least 80% or 88% sequence identity, including sequences comprising conserved motifs associated with increased expression in subcutaneous tissue.

[0097] Regulatory sequences of the invention include enhancer or regulator elements that can increase expression of the nucleic acid encoding the therapeutic protein or peptide. In certain embodiments, the regulatory sequence comprises a sequence having at least 80% sequence identity to any one of SEQ ID NOs: Reg 1-Reg 110, or at least 88% identity. In some embodiments, the regulatory sequence comprises conserved motifs derived from alignment of selected sequences, including Reg 1-Reg 3.

[0098] #15259787vlIt was also discovered that inclusion of:

[0099] • at least one regulatory sequence; and

[0100] • at least one subcutaneously functional polyadenylation sequence

[0101] results in expression levels that can exceed those predicted by the size-dependent regression curve. Constructs comprising these elements consistently demonstrate higher expression than size-matched constructs lacking such elements.

[0102] It was further observed that:

[0103] • inclusion of the regulatory sequence alone results in limited improvement in expression;

[0104] • inclusion of the polyadenylation sequence alone results in limited improvement; whereas:

[0105] • inclusion of both elements results in expression levels greater than those achieved by either element alone.

[0106] This demonstrates a synergistic interaction between regulatory sequences and polyadenylation sequences.

[0107] The regulatory sequence may be positioned:

[0108] • within 0-50 nucleotides downstream of the stop codon;

[0109] • within 0-12 nucleotides downstream of the stop codon; or

[0110] • between 300-500 nucleotides downstream of the stop codon, including 350-420 nucleotides.

[0111] Spacer sequences of 0-12 nucleotides, including 1-3 nucleotides, may be present between the coding sequence and the regulatory sequence.

[0112] Construct size can influence the localization of expression following subcutaneous administration. Smaller constructs (-2200 nt) exhibit greater than 91% localization at the injection site, while larger constructs (>7000 nt) exhibit approximately 30% localization.

[0113] #15259787vlLocalization is measured as the ratio of signal within a defined region of interest at the injection site relative to total body signal.

[0114] Increased localization of expression reduces systemic exposure and is associated with improved safety and tolerability. Accordingly, constructs that maintain localized expression are preferred in some embodiments.

[0115] Importantly, inclusion of the disclosed regulatory and poly adenylation sequences:

[0116] • can increase expression potency;

[0117] • can overcome size-dependent reductions in expression;

[0118] while:

[0119] • not statistically altering biodistribution; and

[0120] • not altering localization of expression.

[0121] Thus, the invention enables increased expression without increased systemic exposure.

[0122] In certain embodiments, specific combinations of regulatory and polyadenylation sequences are used, including:

[0123] • Reg 1 + pA 4

[0124] • Reg 1 + pA 1

[0125] • Reg 3 + pA 4

[0126] Such combinations may provide enhanced expression relative to other pairings.

[0127] In certain embodiments, the construct does not comprise sequences that reduce expression, including sequences having at least 80% identity to SEQ ID NO: EE3.

[0128] The nucleic acid or construct may encode:

[0129] • secreted proteins;

[0130] • peptide hormones;

[0131] • antibodies or antibody fragments;

[0132] #15259787vl• or other therapeutic proteins.

[0133] The constructs may be administered subcutaneously to a subject in need thereof to achieve therapeutic expression of the encoded protein.

[0134] The present invention provides gene therapy constructs that can:

[0135] • overcome size-dependent reductions in expression;

[0136] • exhibit synergistic regulatory sequence and polyadenylation sequence activity;

[0137] • maintain favorable localization; and

[0138] • improve safety and tolerability.

[0139] These features represent a substantial and surprising improvement over conventional gene therapy systems.

[0140] Intracellular proteomic profiles and expressomes of different cell types in the human body can vary significantly (FIG. 1), as such, the proteomic machinery to process or stabilize gene expression, RNA export, RNA stability, RNA turnover, transcription, translation, or other related process will vary greatly cell to cell. As an example, GH1 (Growth Hormone 1), the polyA regulatory sequences for which are at times used in systemically administered gene therapies is expressed at high levels in the liver and spleen, but is below detection cutoff in the subcutis or general adipose tissues.

[0141] Similarly, viruses such as S V40, which typically infect kidney and lung epithelial cells, fibroblasts, hepatocytes, and to a limited extent B cells and are known to utilize cellular machinery present at a high level in those cell types, are generally known to function with lower efficiency in non-permissive cell types such as myocytes and adipocytes. As such, enhancer, regulator, poly adenylation (pA), or post-transcriptional regulator sequences and their combinations that are effective at increasing potency of gene therapy in one cell type is unlikely to be effective in another. Moreover, while a target sequence may be derived from a protein coding gene or a non-coding region of a protein coding gene the protein for which is highly expressed in a given cell type, or

[0142] #15259787vlvice versa be nearly non-detectable in a given cell, our findings demonstrate that the use of such sequences does not necessarily correlate with gene expression in a given cell type.

[0143] In addition, it has been observed that insertion of non-functional DNA blocks decreases potency of non- viral gene therapies as a function of their size and count. Without wishing to be bound by any specific theory, this phenomenon is likely caused by the decreased nuclear import as a function of genetic cassette size in the absence of an active carrier based mechanism, which is present in a number of DNA containing viruses. As such, the length of the construct is generally inversely correlated with its productivity and any utilized enhancer sequence preferably should not only provide a benefit to gene expression, but also overcome the reduction in potency that results from the increase in genetic cassette size, following its introduction.

[0144] The present invention generally provides, at least in part, a number of regulator / enhancer classes (Reg) and a number of polyadenylation (pA) enhancing sequences that can produce both an increase in potency of non-virally delivered subcutaneously administered gene therapy (such as with vectors, which are predominantly localized to the subcutis) as well as regulator / enhancer classes that can provide a potency benefit that overcomes the negative effect of the added genetic cassette size. Similarly, the present invention provides, at least in part, Reg sequences that can provide improved potency such as when used in combinations with given pA sequence classes as well as discloses, at least in part, couplings that can decrease potency of expression.

[0145] More specifically, the present invention provides, at least in part, therapeutic gene therapy formulations for the treatment of human or veterinary pathologies comprised of an adipocyte targeting, subcutaneously administered, or subcutaneously localizing nucleic acid delivery vector, intended for subcutaneous administration or localization of DNA, for production of secreted therapeutic proteins or peptides, formulated to mediate distal or systemic therapeutic effect. Importantly, said gene therapy vector is intended to contain at least one subcutaneous-cell-type-specific regulator polyadenylation motif (pA) and optionally at least one enhancer / regulator (Reg) sequence or motif selected from a class of sequences that promote increased potency of expression following subcutaneous delivery of the therapeutic DNA.

[0146] In line with the present invention, potency of subcutaneously delivered gene therapy treatments can be increased following inclusion of a number of genetic enhancer elements, which are added

[0147] #15259787vldownstream of the coding sequence stop codon, immediately downstream or separated by one of the following spacers: a 1 nucleotide spacer of A, C, T, G, a 2 nucleotide spacer of A / C / T / G followed by A / C / T / G, or a 3 nucleotide spacer A / C / T / G followed by A / C / T / G followed by A / C / T / G, or most ideally TAA, TAG, or TGA. A spacer of up to 12 nucleotides can be used without detrimental effect. Said enhancer sequences can be from a set of any of the following enhancer sequences below, where ‘Reg’ serves as the regulator / enhancer class label:

[0148] > Reg 10 (SEQ ID NO: 1) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCT

[0149] > Reg 11 (SEQ ID NO: 2) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACT[G / A]TATTCTTAACTATGTT GCTCCTTTTACGCT[A / G]TGTGGATA[C / T]GCTGCTTTA[A / T][T / A]GCCT[T / C]TGTATC[T / A][A / T]GCTATTGCTTCCCGTA[T / C]GGCTTTC[A / G]TTTTCTCCTCCTTGTATAAATCCT GGTTGCTGTCTCTTT[A / T][T / A]GAGGAGTTGTGGCCCGTTGTC[A / C]G[G / T]CAACGTG GCGTGGTGTGC[A / T]CTGTGTTTGCTGACGCAACCCCCACTGG[T / C]TGGGGCATTGCC ACCACCTGTCA[G / A]CTCCTTTC[C / T]GGGACTTTCGCTTTCCCCCTCCC[T / G]ATTGCC ACGGC[G / A]GAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCT[C / A]GG[ C / T]T

[0150] In addition, distal enhancers can be used, which are positioned 359-371 nucleotides downstream of the stop codon such as the sequences below:

[0151] > Reg 12 (SEQ ID NO: 11)

[0152] #15259787vlGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0153] Said sequences above are generally categorized as Element 2 and have consistently demonstrated upregulation of gene expression.

[0154] Similar effects can be enabled by structurally interchangeable enhancer sequences including with a 0 to 12 nucleotide spacer following the gene of interest, or ideally a 0 to 3 nucleotide spacer following the gene of interest stop codon or stop codon pair, but with a functional spacer of up to 403 nucleotides:

[0155] > Reg 13 (SEQ ID NO: 3) TCCTTTCCATGGCTGCTCGGTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTG TCTACGTCCCGTCGGCGCTGAATCCCGCGGACGACCCGTCYCGCGGCC

[0156] > Reg 14 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0157] > Reg 15 (SEQ ID NO: 5) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCATTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGGCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0158] > Reg 16 (SEQ ID NO: 6) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACGTCATTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTCGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0159] #15259787vl> Reg 17 (SEQ ID NO: 7) ACTGACAATTCCGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0160] > Reg 18 (SEQ ID NO: 8) GGCACCGACAATTCTGTTGTGTTGTCGCGGAAATACACCTCCTTTCCATGGCTGCTAG GATGTGCTGCCAACTGGATCCTGCGCGGAACGTCCTTTGTTTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCCTCCCGGGGCC

[0161] > Reg 19 (SEQ ID NO: 9) GGCACCGACAATTCTGTTGTGTTGTCACGGAAATACACCTCCTTTCCATGGCTGCTAG GCTGTGCTGCCAACTGGATACTACGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCCTCCCGGGGCC

[0162] > Reg 20 (SEQ ID NO: 10) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTCGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0163] > Reg 21 (SEQ ID NO: 12) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCTTCCCGGGGCC

[0164] > Reg 22 (SEQ ID NO: 13) TCCTTTCCATGGCTGCTCGGCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTG TCTACGTCCCGTCGGCGCTGAATCCCGCGGACGACCCGTCTCGCGGCC

[0165] > Reg 23 (SEQ ID NO: 4)

[0166] #15259787vlACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0167] > Reg 24 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0168] > Reg 25 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0169] > Reg 26 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0170] > Reg 27 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0171] > Reg 28 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0172] > Reg 29 (SEQ ID NO: 4)

[0173] #15259787vlACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0174] > Reg 30 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0175] > Reg 30 (SEQ ID NO: 11) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0176] > Reg 31 (SEQ ID NO: 14) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGACTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0177] > Reg 32 (SEQ ID NO: 15) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0178] > Reg 33 (SEQ ID NO: 15) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0179] #15259787vl> Reg 34 (SEQ ID NO: 16) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0180] > Reg 35 (SEQ ID NO: 16) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0181] > Reg 36 (SEQ ID NO: 17) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCATCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0182] > Reg 37 (SEQ ID NO: 16) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0183] > Reg 38 (SEQ ID NO: 18) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTGCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0184] > Reg 39 (SEQ ID NO: 19)

[0185] #15259787vlGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTATGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTGCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0186] > Reg 40 (SEQ ID NO: 20) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCG GCCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTGCTGCGGCCTCTTC CACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTGCCTTTGGGCCGCCTCCCCGC

[0187] > Reg 41 (SEQ ID NO: 21) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTAACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGG CCCTCAATCCAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTCC ACGTCTTCGCCTTCACCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0188] > Reg 42 (SEQ ID NO: 22) GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTAACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGG CCCTCATCCAAGCGGACCTCCCTTCCCGCGGCCTGCTGCCGGTTCTGCGGCCTCTTCC ACGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0189] > Reg 43 (SEQ ID NO: 23) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCC CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGCTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGACCTCCGACGAGTCGGATTTCCCTTTGGGCCGCCTCCCCGC

[0190] > Reg 44 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT

[0191] #15259787vlCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0192] > Reg 45 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0193] > Reg 46 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0194] > Reg 47 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0195] > Reg 48 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0196] > Reg 49 (SEQ ID NO: 24) TGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCT CGCCTGTGTTGCCAACTGGATCCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCT CTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCCGC GTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0197] #15259787vl> Reg 50 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0198] > Reg 51 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0199] > Reg 51 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0200] > Reg 52 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0201] > Reg 53 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0202] > Reg 54 (SEQ ID NO: 25)

[0203] #15259787vlGTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0204] > Reg 55 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0205] > Reg 56 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0206] > Reg 57 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0207] > Reg 58 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0208] > Reg 59 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG

[0209] #15259787vlCTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0210] > Reg 60 (SEQ ID NO: 26) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGACCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0211] > Reg 61 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0212] > Reg 62 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0213] > Reg 63 (SEQ ID NO: 25) GTTGGGCACTGATAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATCCTACGCGGGACGTCCTTCTGCTACGTCCCTTCAG CTCTCAATCCAGCGGACCTCCCTTCCCGAGGCCTTCTGCCGGTTCTGCGGCCTCTCCC GCGTCTTCGCTTTCGGCCTCCGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGC

[0214] > Reg 64 (SEQ ID NO: 27) GTTGGGCACTGACAACTCCGTGGTTCTCTCGGGCAAACTGACTTCCTTCCCATGGCT GCTCGCCTGTGTTGCCAACTGGATTCTTCGCGGGACGTCGTTCTGCTACGTCCCTTCG GCAGCGAATCCAGCGGACCTGCCGTCTCGGGGCCTTCTGCCGGCTCTGCGTCCCGTG CCGACTCTCCGCTTCCGTCCGCAGCTGAGTCGCATCTCCCTTTGGGCCGCCTCCCCGC

[0215] #15259787vl> Reg 65 (SEQ ID NO: 28) GTTGGGCACTGACAACTCCGTGGTTCTTTCGGGCAAACTGACTTCCTATCCATGGCTG CTCGCCTGTGTTGCCAACTGGATTCTTCGCGGGACGTCGTTCTGCTACGTCCCTTCGG CAGCGAATCCGGCGGACCTGCCGTCTCGAGGCCTTCTGCCGGCTCTGCATCCCGTGC CGACTCTCCGCTTCCGTCCGCAGCTGAGTCGCATCTCCCTTTGGGCCGCCTCCCCGC

[0216] > Reg 66 (SEQ ID NO: 29) GTTGGGCACTGATAACTCCGTGGTCCTCTCCGGTAAGCTAACTTCGTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATTCTTCGCGGGACGTCCTTCTGTTACGTCCCCTCCG CGGACAACCCAGCGGACCTTCCGTCTCGGGGACTTCTGCCGGCTCTCCGTCCTCTGC CGCTTCTGCGTTTTCGTCCGGTCACCAAGCGGATATCCCTGTGGGCCGCCTCCCCGC

[0217] > Reg 67 (SEQ ID NO: 29) GTTGGGCACTGATAACTCCGTGGTCCTCTCCGGTAAGCTAACTTCGTTTCCATGGCTG CTCGCCTGTGTTGCCAACTGGATTCTTCGCGGGACGTCCTTCTGTTACGTCCCCTCCG CGGACAACCCAGCGGACCTTCCGTCTCGGGGACTTCTGCCGGCTCTCCGTCCTCTGC CGCTTCTGCGTTTTCGTCCGGTCACCAAGCGGATATCCCTGTGGGCCGCCTCCCCGC

[0218] > Reg 68 (SEQ ID NO: 30) GACAATTCCGTTGTTTTGTCGCGGAAGTATACGTCCTTTCCATGGCTGCTAGGTTGTGC TGCCAACTGGATACTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCC GCGGACGACCCTTCTCGGGGCC

[0219] > Reg 69 (SEQ ID NO: 30) GACAATTCCGTTGTTTTGTCGCGGAAGTATACGTCCTTTCCATGGCTGCTAGGTTGTGC TGCCAACTGGATACTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCC GCGGACGACCCTTCTCGGGGCC

[0220] > Reg 70 (SEQ ID NO: 31)

[0221] #15259787vlGGCACTGACAACTCTGTTGTTCTGTCGCGGAAATATACGTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTCGTTTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0222] > Reg 71 (SEQ ID NO: 32) GACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0223] > Reg 72 (SEQ ID NO: 32) GACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0224] > Reg 73 (SEQ ID NO: 32) GACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0225] > Reg 74 (SEQ ID NO: 32) GACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0226] > Reg 75 (SEQ ID NO: 32) GACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0227] > Reg 76 (SEQ ID NO: 32)

[0228] #15259787vlGACAATACCGTCGTGTGCTCCGGGAAGTTCACGCACTTCCCATGGCTGCTCGGCTGC GTTGCGAATTGGATGCTGCGCGGGACGTCGTTCTGCTACGTCCCTTCGGCGCTGAATC CCGCGGAC

[0229] > Reg 77 (SEQ ID NO: 33) GGCACTGACAACTCCGTTGTCCTGTCTCGGAAGTACACCTCCTTCCCATGGCTGCTCG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCTGCGGAC

[0230] > Reg 78 (SEQ ID NO: 34) GGCACCGACAACTCTGTCGTGCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTAG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCAGCGGAC

[0231] > Reg 79 (SEQ ID NO: 35) GGCACCGACAACTCTGTTGTCCTCTCGCGGAAGTACACCTCCTTTCCATGGCTGCTAG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCAGCGGAC

[0232] > Reg 80 (SEQ ID NO: 36) GGCACTGACAACTCTGTTGTCCTGTCTCGGAAGTACACCTCCTTCCCATGGCTGCTCG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCTGCGGAC

[0233] > Reg 81 (SEQ ID NO: 36) GGCACTGACAACTCTGTTGTCCTGTCTCGGAAGTACACCTCCTTCCCATGGCTGCTCG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCTGCGGAC

[0234] > Reg 82 (SEQ ID NO: 37)

[0235] #15259787vlACTGATAATTCCGTCGTCCTTTCGCGGAAATATACGTCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCTGCGGAC

[0236] > Reg 83 (SEQ ID NO: 38) GGCACTGACAACTCTGTGGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTAG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGAC

[0237] > Reg 84 (SEQ ID NO: 39) TCCTTTCCATGGCTGCTCGGCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTG GCTACGTCCCGTCGGCGCTGAATCCCGCGGAC

[0238] > Reg 85 (SEQ ID NO: 40) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACCTCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCAGCGGAC

[0239] > Reg 86 (SEQ ID NO: 41) GGCACTGACAACTCCGTTGTCCTATCTCGGAAGTACACCTCCTTCCCATGGCTGCTCG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCTGCGGAC

[0240] > Reg 87 (SEQ ID NO: 39) TCCTTTCCATGGCTGCTCGGCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTG GCTACGTCCCGTCGGCGCTGAATCCCGCGGAC

[0241] > Reg 88 (SEQ ID NO: 42) GGCACTGACAACTCCGTTGTCCTTTCTCGGAAGTACACCTCCTTCCCATGGCTGCTCG GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCTGCGGAC

[0242] #15259787vl> Reg 89 (SEQ ID NO: 43) ACTGACAATTCTGTCGTCTTGTCGCGGAAATATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATACTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCTGCGGAC

[0243] > Reg 90 (SEQ ID NO: 10) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTCGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0244] > Reg 91 (SEQ ID NO: 44) ACTGACAATTCTGTCGTGCTGTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0245] > Reg 92 (SEQ ID NO: 45) TCCTTTCCATGGCTGCTAGGCTGTGCTGCCAACTGGATTCTGCGCGGGACGTCCTTTG TCTACGTCCCGTCGGCGCTGAATCCCGCGGACGACCCTTCTCGGGGCC

[0246] > Reg 93 (SEQ ID NO: 46) ACTGACAATTCTGTCGTGCTCTCTCGCAAGTATACGTCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0247] > Reg 94 (SEQ ID NO: 6) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACGTCATTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTCGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0248] > Reg 95 (SEQ ID NO: 47)

[0249] #15259787vlACTGACAATTCTGTGGTGTTATCCCGCAAGTATACATCGTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0250] > Reg 96 (SEQ ID NO: 48) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACGTCCTTTCCATGGCTGCTAGGCT GTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGA ATCCCGCGGACGACCCCTCCCGGGGCC

[0251] > Reg 97 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0252] > Reg 98 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0253] > Reg 99 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0254] > Reg 100 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0255] > Reg 101 (SEQ ID NO: 49)

[0256] #15259787vlGGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0257] > Reg 102 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0258] > Reg 103 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0259] > Reg 104 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0260] > Reg 105 (SEQ ID NO: 49) GGCACTGACAACTCTGTTGTCCTCTCTCGGAAGTACACCTCCTTTCCATGGCTGCTCG GTTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCT GAATCCCGCGGACGACCCTTCTCGGGGCC

[0261] > Reg 106 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0262] > Reg 107 (SEQ ID NO: 4)

[0263] #15259787vlACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0264] > Reg 108 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0265] > Reg 109 (SEQ ID NO: 4) ACTGACAATTCTGTCGTGCTCTCCCGCAAGTATACATCCTTTCCATGGCTGCTAGGCTG TGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTCTACGTCCCGTCGGCGCTGAAT CCCGCGGACGACCCCTCCCGGGGCC

[0266] Other distal enhancer sequences which can be used to increase potency of gene expression include the following set of sequences that are positioned 0-12 nucleotides downstream of the stop codon, but most ideally 403-415 nucleotides downstream of the stop codon of the therapeutic transgene delivered as part of the subcutaneously administered gene therapy:

[0267] > Reg 110 (SEQ ID NO: 50) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGC

[0268] #15259787vlAnd yet other parts of known distal enhancer sequences were identified as specifically reducing gene expression of subcutaneously administered gene therapy. One such sequence is labelled EE3 below and should be excluded from any enhancer sequence utilized in a therapeutic construct to increase potency, unless a compensating genetic sequence is utilized to increase the potency of the therapeutic construct:

[0269] > EE3 (SEQ ID NO: 51) GAGCATCTTACCGCCATTTATACCCATATTTGTTCTGTTTTTCTTGATTTGGGTATACATT TAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATT ACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTATTTAC GCTCTGTTCCTG[T / A]T

[0270] Sequence alignment of top 3 performing regulatory sequences is shown in FIG.5 and can be used to derive sequences with similarity scores of in excess of 88% identity to achieve the same or comparable effect on potency of subcutaneously administered, or adipocyte targeting, or generally subcutaneously localizing gene therapy treatments. Motifs derived from sequence alignment can be utilized in lieu of or as part of enhancer sequences or other sequence to increase the potency of gene expression. Said motifs can be derived from similarity or differential presence between expression promoting and expression educing constructs.

[0271] Other sequences which can be used with specific auxiliary sequences such as pA sequences, or other enhancers or in conjunction with pA consensus sequences include sequences below, which should be positioned immediately downstream of the stop codon or two stop codons or with a CI-12 nucleotide spacer following the last stop codon of the therapeutic transgene delivered by the subcutaneously administered, subcutaneously localizing, or adipocyte targeting gene therapy: > Reg 3 (SEQ ID NO: 52) ATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCC CGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGA

[0272] #15259787vlACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGA CAATTCCGTGGTG

[0273] Or alternatively:

[0274] > Reg 2 (SEQ ID NO: 53) GAGCATCTTACCGCCATTTATACCCATATTTGTTCTGTTTTTCTTGATTTGGGTATACATT TAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATT ACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTATTTAC GCTCTGTTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATT CTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTA GCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCT CTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTTG CTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGGGA CTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCG CTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTTGTC

[0275] > Reg 5 (SEQ ID NO: 54) AATCAACCCTTAGATTATAAAATATGTGAAAGGTTGACGGGCATTCTTAATTATGTTGC TCCTTTTACCAAATGTGGTTATGCTGCTTTACTGCCTTTATATCAAGCTATTGCTTCTCA TACTGCTTTTGTTTTCTCCTCCTTATATAAAAACTGGTTACTGTCACTTTATGGTGAGTT GTGGCCCGTTGCCAGACAACGTGGTGTGGTGTGCTCTGTGTTTGCTGACGCAACTCC CACTGGTTGGGGCATTTGCACCACCTGTCAACTCATTTCCGGTACTTTCGGTTTCTCA CTTCCGATTGCTACCGCGGAGCTTATAGCCGCCTGCCTTGCTCGCTGCTGGACAGGAG CTCGGTTGTTGGGCACTGATAACTCCGTGGTCCTCTCCGGTAAGCTAACTTCGTTTCC ATGGCTGCTCGCCTGTGTTGCCAACTGGATTCTTCGCGGGACGTCCTTCTGTTACGTC CCCTCCGCGGACAACCCAGCGGACCTTCCGTCTCGGGGACTTCTGCCGGCTCTCCGT CCTCTGCCGCTTCTGCGTTTTCGTCCGGTCACCAAGCGGATATCCCTGTGGGCCGCCT CCCCGCCTG

[0276] > Reg 6 (SEQ ID NO: 55)

[0277] #15259787vlGATCCAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTAT GTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCT TCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAG GAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCA ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTT TCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGAC AGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTC CTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGC TACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTC TGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGC CGCCTCCCCGCCTGGGATC

[0278] > Reg 7 (SEQ ID NO: 56) AATCAACCTCTGGATTACAAAATTTCTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAACTCCTTTCCGGGACTTACGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGACTCGGATCTCCCTTTGGGCCGCC TCCCCGC

[0279] > Reg 8 (SEQ ID NO: 57) AATCAACCTCTGGATTACAAAATTTCTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAACTCCTTTCCGGGACTTACGCTTTCCCC

[0280] #15259787vlCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGACTCGGATCTCCCTTTGGGCCGCC TCCCCG

[0281] > Reg 9 (SEQ ID NO: 58) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTACTTCCCG TACGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTATCAACTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATTGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCAACTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGTTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGC

[0282] Or most preferably especially for non-viral vector gene therapies (or sequences with query coverage of >50% and identity of over 72%):

[0283] > Reg 1 (SEQ ID NO: 59) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG

[0284] #15259787vlTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGC

[0285] > Reg 4 (SEQ ID NO: 60) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACT ATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTG CTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATG AGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACG CAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGC TTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGG ACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACG TCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCT GCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGC TCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGG GCCGCCTCCCCGC

[0286] Reg sequences above may be followed by a 0-12 nucleotide spacer, some example sequences, which may be used as spacer sequences include: A / T / G / C, A / T / G / C followed by A / T / G / C, A / T / G / C followed by A / T / G / C followed by A / T / G / C, CTG, CTGCAG, CTGCAGACA, or

[0287] #15259787vlCTGCAGACATGA (SEQ ID NO: 117). Alternatively, constructs may choose to exclude Reg sequences and utilize high potency adipocyte consensus pA sequences alone or in conjunction with specialized Reg sequences.

[0288] Subcutaneously delivered, subcutaneously targeting, subcutaneously localizing, or adipocyte targeting gene therapies may employ the following consensus motifs, sequences, or potency expressing sequences 0 to 34, ideally 17 to 34 nt downstream of enhancer, which itself follows the gene of interest with a 0-12 nucleotide spacer. Should such an enhancer not be utilized, the sequence can follow the gene of interest 0 to 34, ideally 17 to 34 nt downstream of the stop codon:

[0289] > pA 10 (SEQ ID NO: 61) CCCCTCCCC[C / A]GTGCCT[T / C]CCTTG[A / G]CCCTGGAAG[G / T]TGCCACTCC Alternatively, subcutaneously delivered, subcutaneously targeting, subcutaneously localizing, or adipocyte targeting gene therapies may employ the following consensus motifs, sequences, or potency expressing sequences 130-140, ideally 147-157 nt downstream of enhancer, which itself follows the gene of interest with a 0-12 nucleotide spacer.

[0290] > pA 11 (SEQ ID NO: 62)

[0291] [C / T]T[G / A] [G / T]GGGGTGG[G / A]G[T / G]GGGG[C / T] [A / G]G[G / T] A[C / T]

[0292] Should such an enhancer not be utilized, the sequence SEQ ID NO: 62 can follow the gene of interest 130-140, ideally 147-157 nt downstream of the stop codon.

[0293] Alternatively, subcutaneously delivered, subcutaneously targeting, subcutaneously localizing, or adipocyte targeting gene therapies may employ the following consensus motifs, sequences, or potency expressing sequences 156-164, ideally 173-181 nt downstream of enhancer, which itself follows the gene of interest with a 0-12 nucleotide spacer.

[0294] > pA 12 (SEQ ID NO: 63)

[0295] AGCAAGGGG[G / C]A[G / A]G[A / T]T[T / G]GG[G / A]

[0296] Should such an enhancer not be utilized, the sequence SEQ ID NO: 63 can follow the gene of interest 156-164, ideally 173-181 nt downstream of the stop codon.

[0297] #15259787vlMoreover, the following sequences with a >88% identity and statistical significance can be used with non-viral gene therapies 0 to 192 nt downstream of enhancer, which itself follows the gene of interest with a 0-12 nucleotide spacer. Should such an enhancer not be utilized, the sequences can follow the gene of interest 0 to 192 nt downstream of the stop codon.

[0298] > pA 13 (SEQ ID NO: 121) GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACT CCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGT GTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGG AAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGC ACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAG CCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTT TTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAG GTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTC CCTTCCCTGTCCTT

[0299] > pA 14 (SEQ ID NO: 64) CCAGGCTGGAGTGCAATGGTGCAATCTTGGCTCACTGCAACCTCCGCCTCCTGGGTT CAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAAGCACTGCCACCAT GCCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCGCCACATTGGCCAGGCTA GTCTCAAACTCCTGATCTCAGGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGAT TACAGGTGTGAGCCACCGCTCC

[0300] > pA 15 (SEQ ID NO: 65) CCAGGCTGGAGTGCATTGGCACAATCTCAGCTCACTGCAAACTCCGCCTCCTGGGTT CAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCGCATGCCACC ATGCTCAGCGAATTTTTGTATTTTTAGTAGAGACGAGGTTTCACCATGTTGTCCAGGCT GGTCTCAAACTCCTGACCTCAGGTGATCCACCCTCCTTGGCCTCCCAAAGTGCTGGG ATTACAGGCGTGAGCCA

[0301] > pA 16 (SEQ ID NO: 66)

[0302] #15259787vlCCAGGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAACGTCCGCCTCCTGGGTT CAAGTGATTCTCCTGCCTCAGCCTCCCGAGTAGCTCGGATTACAGGCATGCATCACCA GGCCCTGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTG GTCTCGAACTCCTGACCTCAGGTGATCTGCCTGCCTCGGCCTCCCAAAATGCTGGGAT TACAGCCGTGAGCCACT

[0303] > pA 17 (SEQ ID NO: 67) CCAGGCTGGAGTGCAATGGCACAATCTTGGCTCATTGCAACCTCCGCCTCCTAGGTTC AAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCATGCATCACCAT GCTCAGCTAATTTTGTATTTTTTAGTAGAGACGGGGTTTCTCCATGTTGGTCAGGCTGG TCTCGAACTCCCGACCTCAGGTGATCGGCCCACCTTGGCCTCCCAAAGTGCTGGGAT TACAGGCATGAGCCACTGC

[0304] In a similar approach, the following sequences with a >88% identity match to the consensus sequences query and statistical significance can be used with non-viral gene therapies 130-140, ideally 147-157 nt downstream of enhancer, which itself follows the gene of interest with a 0-12 nucleotide spacer. Should such an enhancer not be utilized, the sequence can follow the gene of interest 130-140, ideally 147-157 nt downstream of the stop codon.

[0305] > pA 18 (SEQ ID NO: 68) AGGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATAT GGTGAAACCCCGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGCATGC CTGGAATCCCAACAACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGG CGGAGATTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCTTGGTTCCCAATAGA CCCCGCAGGCCCTACAGGTTGTCTTCCCAACTTGCCCCTTGCTCCATACCACCCCCCT CCACCCCATAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAACTTAATTTTA TTAGGACAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACT GGGGAGGGG

[0306] > pA 19 (SEQ ID NO: 69)

[0307] #15259787vlAGGCCGAGGCGGGCGGATTACCTGAGGTCAGGAGATGGAGACCAGACTGGCCAATA TGGTGAAACCCCGTCTCTACCAAAAATACAAAAATTAGCTGAGCCTGGTCGTGCATG CCTGGAATCCCAACTATTCGGGAGACTGAGGCAGGAGAATCGCTTGAACCCAGGAGG CGGAGATTGCAGCGAGCCAAGATCGTGCCACTGCACTCCAGCCTGGTTCCCAATAGA CCCTGAAGGCCCTACAGGTTGTCTTCCCAACCTGCCCCTTGCTCCATACCACCCGCCT CCACCCCATAATATTATACAAGGACACCTAGTCAAACAAAATGATGCAACTTAATTTTA TTAGGACAAGGCTGGTGGGCACTGGAGTAGCACCTTCCACGACCAGGAGAGGCACT GGGGAGGGG

[0308] > pA20 (SEQIDNO: 70) AGGCCAAGGTGGGTGGATCACTTGAGGTCAGGAGTTGGAGACCAGCCTGGCCAACA TGGTGAAACCTCGTCTCTACTAAAAATATAAAAATTAGCTGGGCGTGGTGGCGCATGC CTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGC AGAGGTTGCAGTGAGCCGAGATTGTACCACCGCACTCCAGCCTGG

[0309] > pA21 (SEQIDNO: 71) AGGCCAAGGTGGGTGGACCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACA TGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGCGCATG CCTGTAATCCCAGCTACTAGGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGG CAGGGGTAGCAGTGAGCCGAGATAGTGCCACTGCACTCCAGCCTGG

[0310] > pA22 (SEQIDNO: 72) AGGCCGAGGCAGGCAGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACA TGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCAGGGCCTGGTGATGCATGC CTGTAATCCGAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGG CGGACGTTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCCTGG

[0311] > pA23 (SEQIDNO: 73) CAAGGCGGGTGGATCACTTGAGGCCAGGAGTTCGAGACCAGCCTGGCCAAGATGGT GAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCATGGTGGTGGGTGCCTGT

[0312] #15259787vlAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCGGA GGTTGCAGTGAGCTGAGATTGTGCCACTGCACTCCAGCCTGG

[0313] > pA24 (SEQIDNO: 74) AGGCCAGGGTGGGCAGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGACCAACA TGGTGAAACCCCATCTCTACTAAAAATGCAAAAATTAGCCAGGTGTAGTGACACATGC CTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGGATCGCTTGAACCTGGGAGGC AGAGGTTGCAGTGAGCCAAGATCATGCCATTGCACTCCAGCTTGG

[0314] > pA25 (SEQIDNO: 75) AGGCGGGTGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGCGA AACCCCATCTCTACTAAAAACACAAAAATTAGCCGGGCATGGTGATGTGTGCCTGTAA TCCCAGATACTCAGGAGGCTGAGGCAGGAGAATTGCTTGAATCCAGGAGGCGGAGG TTGCAGTGAGCCGAGATCGAGCCACTGTACTCCAGCCTGG

[0315] > pA26 (SEQIDNO: 76) CCAGGCTGGAGTGCAATGGCATGATCTCGGCTCACTGCAACCTCCGCCTCTTGGGTTC AAGTGATTCTCCTGCCTCAGCCTCCTGCGTAGCTGGGATTACAGGTACCCACCACCAT GCCCAGTTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCAGGTTGGCCAGGCTG GTCTCAAACTCCTGACCTCAGGTGATCCACCCACCTAGGCCT

[0316] > pA27 (SEQIDNO: 77) AGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAATGTGGTGAAACCCCATC TCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGTGCATGCCTGTAATCCCAGCTA CTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGCAGTGA GCCAAGATGGCGCCATTGCACTCCAGCCTGG

[0317] > pA28 (SEQIDNO: 78) CCAAGCTGGAGTGCAGTGGTATGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTC AAGCAATTCTCCTGCCTCAGCCTCCCGAGTGGCTGGGATTACAGGCACGCAGCACCA CGCCCAGCTAATTTTGTATTTTTAGTAGAGACGAGGTTTCACCATATTGGCCAGGCTGG TCTCAAACTCCTGATCTCAGGTGATCCACCCACCTCGGCCT

[0318] #15259787vl> pA29 (SEQIDNO: 79) AGGCCGAGGCGGGTGGATCACCTGTGGTCAGGAGTTCGAGACCAGCCTGGCCAACA TGGTGAAACCCCTTCTCTACTAAAAACACAAAAATTAGCTGGGCGTGGTGGTAGGTG CCTGTAATCCCAACTACTCGGGAGGGTGAGGCAGGAGAATCGCTTGAACCCGGGAG GCGGAGGTTGCAGTGAGCCAAGATTGCGCCACTGCACTCCAGCCTGG

[0319] > pA 30 (SEQ ID NO: 80) CCAGGCTGGAGTGCAGTGGCGCAGTCTCCACTCACTGCAACCTCTGCCTCCTGGGTT CAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATGACAGGCGGGCATCACC ACGCCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGC TGGTCTCGAACTCCTGAGCTCAGGTGATCTGCCCACCTCGGCCT

[0320] > pA31 (SEQIDNO: 81) AGGCCAAGGTGGGCAGATCACCTGAGATCAGGAGTTTGAGACCAGCCTGGCCAACA TAGTGAAACCCTGTCTCTACTAAAAATACAAAATTAGCTGGGCGTGGTGGCACATGCC TGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGC GGAGGTTGCAGTGAGCCGAGATTGTGCCACTGCACTCCAGC

[0321] > pA 32 (SEQ ID NO: 82) AGGCCAAGGTGGGTGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACA TGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGGCCTGGTGGTGCATA CCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGG TGGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCATTCCAGCCTGG

[0322] > pA 33 (SEQ ID NO: 83) GATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCGTCT CTACTAAAAATACAAAAATTAGCCAGGCGTGGTGGTGCATGCCTGTAATCCCAGTTAC TCCGGAGGCTAAGGCAGGAGAATCGCTTGAACCCAGGAGGCAGAGATTGCAGTGAG CCAAGACTGTGCCACTGCACTCCAGCCTGG

[0323] > pA 34 (SEQ ID NO: 84)

[0324] #15259787vlCCAGGCTGGAGTGCAGTGGTACGATCTTGGCTCACTGCACCTTCCACCTCCTGGGTTC AAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCATGCGCTACCAC GCTCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGTCCAGGCTGG TCTCCAACTCCTAGCCTCAGGTCATCTGCCCACCTCGGCCT

[0325] > pA 35 (SEQ ID NO: 85) AGGCCGAGGTGGGCAGATCATCTGAGGTCAGGAGTTTGAGACCAGCCTTGGCCAAC GTGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCTGAGCATGGTGGTGCAA GCCTGTAATCCCAGCTACTCAGGAGGTTGAGGCAGGAGAATCGCTTGAACCCAGGAG GCAGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCATTCCAGCCTGG

[0326] > pA 36 (SEQ ID NO: 86) AGGCCGAGGTGGGCAGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACA TGGTGAAACCCCATCTTTATTAAAAACACAAAAATTAGCTGGGCGTGGTGGTGGGCG CCTGTAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGGAGG TGGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCCTGG

[0327] > pA 37 (SEQ ID NO: 82) AGGCCAAGGTGGGTGGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACA TGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGGCCTGGTGGTGCATA CCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGG TGGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCATTCCAGCCTGG

[0328] > pA 38 (SEQ ID NO: 83) GATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCGTCT CTACTAAAAATACAAAAATTAGCCAGGCGTGGTGGTGCATGCCTGTAATCCCAGTTAC TCCGGAGGCTAAGGCAGGAGAATCGCTTGAACCCAGGAGGCAGAGATTGCAGTGAG CCAAGACTGTGCCACTGCACTCCAGCCTGG

[0329] > pA 39 (SEQ ID NO: 84) CCAGGCTGGAGTGCAGTGGTACGATCTTGGCTCACTGCACCTTCCACCTCCTGGGTTC AAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCATGCGCTACCAC

[0330] #15259787vlGCTCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGTCCAGGCTGG TCTCCAACTCCTAGCCTCAGGTCATCTGCCCACCTCGGCCT

[0331] > pA 40 (SEQ ID NO: 85) AGGCCGAGGTGGGCAGATCATCTGAGGTCAGGAGTTTGAGACCAGCCTTGGCCAAC GTGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCTGAGCATGGTGGTGCAA GCCTGTAATCCCAGCTACTCAGGAGGTTGAGGCAGGAGAATCGCTTGAACCCAGGAG GCAGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCATTCCAGCCTGG

[0332] > pA 41 (SEQ ID NO: 86) AGGCCGAGGTGGGCAGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACA TGGTGAAACCCCATCTTTATTAAAAACACAAAAATTAGCTGGGCGTGGTGGTGGGCG CCTGTAATCCCAGCTACTCTGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGGAGG TGGAGGTTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCCTGG

[0333] > pA 42 (SEQ ID NO: 87) AGGCCAAGGTGGAAGGATCACCTGAGGTCAGGAGTTCCAGACCAGCCTGGCCAACA TGGCAAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGTGTGGTGGTACATGA CTGTAATCCCAGCTACTCCGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGC GGAGGTTGCAGTGAGCCAAGATTGCACCACTGCACTCCAGCCTGG

[0334] > pA 43 (SEQ ID NO: 68) AGGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATAT GGTGAAACCCCGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGCATGC CTGGAATCCCAACAACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGG CGGAGATTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCTTGGTTCCCAATAGA CCCCGCAGGCCCTACAGGTTGTCTTCCCAACTTGCCCCTTGCTCCATACCACCCCCCT CCACCCCATAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAACTTAATTTTA TTAGGACAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACT GGGGAGGGG

[0335] > pA 44 (SEQ ID NO: 69)

[0336] #15259787vlAGGCCGAGGCGGGCGGATTACCTGAGGTCAGGAGATGGAGACCAGACTGGCCAATA TGGTGAAACCCCGTCTCTACCAAAAATACAAAAATTAGCTGAGCCTGGTCGTGCATG CCTGGAATCCCAACTATTCGGGAGACTGAGGCAGGAGAATCGCTTGAACCCAGGAGG CGGAGATTGCAGCGAGCCAAGATCGTGCCACTGCACTCCAGCCTGGTTCCCAATAGA CCCTGAAGGCCCTACAGGTTGTCTTCCCAACCTGCCCCTTGCTCCATACCACCCGCCT CCACCCCATAATATTATACAAGGACACCTAGTCAAACAAAATGATGCAACTTAATTTTA TTAGGACAAGGCTGGTGGGCACTGGAGTAGCACCTTCCACGACCAGGAGAGGCACT GGGGAGGGG

[0337] > pA 45 (SEQ ID NO: 70) AGGCCAAGGTGGGTGGATCACTTGAGGTCAGGAGTTGGAGACCAGCCTGGCCAACA TGGTGAAACCTCGTCTCTACTAAAAATATAAAAATTAGCTGGGCGTGGTGGCGCATGC CTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATTGCTTGAACCCGGGAGGC AGAGGTTGCAGTGAGCCGAGATTGTACCACCGCACTCCAGCCTGG

[0338] > pA 46 (SEQ ID NO: 88) AGGCCAAGGTGGGCCGATCACCTGAGGTCGGGAGTTCGAGACCAGCCTGACCAACA TGGAGAAACCCCGTCTCTACTAAAAAATACAAAATTAGCTGAGCATGGTGATGCATGC CTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCTAGGAGGC GGAGGTTGCAATGAGCCAAGATTGTGCCATTGCACTCCAGCCTGG

[0339] > pA 47 (SEQ ID NO: 89) GATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGTGAAACCCCGTCT CTACTAAAAATACAAAAATTATCCGGGCCTGGTGGTGCACGCCTGTAATCCCAGCTAC TTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCAGAGGTTGCAGTGAG CCAAGATTGGGCCACTGCACTCCAGCCTGG

[0340] > pA 48 (SEQ ID NO: 90) AGGCCAAGGTGGGTGGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACA TGGTGAAGCCCCGTCTCTACCAAAAATACAAAAATTAGCTGGGCATGATGGTGGGTG

[0341] #15259787vlCCTGTAATCCCAGCTACTTGGTAGGCTGAGGCAGGAGAATCACTTGAACCCGGGAGG CGGAGGTTGCAGTGAGCCAAGATTGCACCACTGCACTCCAGCCTGG

[0342] > pA49 (SEQ ID NO: 91) AGGCCGAGGCAGGTGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACA TGGCGAAACCCCTTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTAGTGCATGC CTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGT GGAGGTTGCAGTGAGCCGAGATTGTGCCACTGCACTCCA

[0343] > pA 50 (SEQ ID NO: 92) CCAGGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAAGCTCTGCCTCCCGGGTT CAAGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCACACACCACC ACACCCGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCT GGTCTCAAACTCCTGACCTCAAGTGATCCACCCACCTTGGCCT

[0344] > pA 51 (SEQ ID NO: 93) CCAGGCTGGAGTGCAGTGGCACAATCTCGGCTCACTGCAACCTCTGCCTCCCGGGTT CAAGGGATTCTCCTGCTTCAGCCTCCTGAGTGGTTGGGATTACAGGCACGCGCCACC ACGCCCAGCTAATGTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGC TGGTCTCGAACTCCTGACCTCAAGTGATCCACCCGCCTTGGCCT

[0345] > pA 52 (SEQ ID NO: 94) CCAGGCTGGAGTGCAGTGGCACAATCTCGGCTCACTGCAACCTGTGCCTCCTGGGTT CAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCATGTGCCACC ATGCCCAGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCT GGTCTTGAACTCCTGACCTCAGGTGATCCACCCGCCTTGGCCT

[0346] Sequence alignment of top 3 performing regulatory sequences is shown in FIG.7 and can be used to derive sequences with similarity scores of in excess of 88% identity to achieve the same or comparable effect on potency of subcutaneously administered, or adipocyte targeting, or generally subcutaneously localizing gene therapy treatments. Motifs derived from sequence alignment can be utilized in lieu of or as part of enhancer sequences or other sequence to increase the potency of

[0347] #15259787vlgene expression. Said motifs can be derived from similarity or differential presence between expression promoting and expression educing constructs.

[0348] The following sequences can be used 0-12 nt downstream of the stop codon or 0-12 nt downstream of the enhancer sequence to maximize potency of expression.

[0349] > pA 1 (SEQ ID NO: 122) CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACC CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGG AGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0350] > pA 2 (SEQ ID NO: 121) GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACT CCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGT GTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGG AAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGC ACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAG CCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTT TTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAG GTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTC CCTTCCCTGTCCTT

[0351] > pA 3 (SEQ ID NO: 118) AATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTG

[0352] > pA 4 (SEQ ID NO: 95) TAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCT TTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAC AAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0353] > pA 5 (SEQ ID NO: 96)

[0354] #15259787vlGATCCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATG CCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAA TAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCA TTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCCATATGCTGG CTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCCCCTGC TGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATATTTTG TTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTCTCTTATGGAGATCCCTCGACGCGC

[0355] > pA 5 (o) (SEQ ID NO: 97) CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAA AAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCT GCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGA GGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0356] Alignment for derivation of consensus sequences without the user of the optimized pA 5 sequence (pA 5 (o) (SEQ ID NO: 97)) (FIG. 8). It confirms the previously identified motifs and suggests two identifies two additional sets of motifs, which can (a) enhance expression of subcutaneously administered gene therapies when coupled with Reg sequences and (b) enhance expression of subcutaneously administered gene therapies when used downstream of the gene of interest stop codon with a 0-12 nucleotide spacer without the use of additional Reg sequences.

[0357] > pA (b 1) when positioned starting 0-12 nucleotides following the stop codon:

[0358] TAAGATACATTGATGAGTTTGGACCA (SEQ ID NO: 123)

[0359] > pA (b 2) when positioned starting 70 to 82 nucleotides following the stop codon:

[0360] TTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAA (SEQ ID NO: 124) > pA (a 1) when positioned starting 0 to 12 or 11 to 23 nucleotides following the stop codon:

[0361] #15259787vl[A / G]G[T / G]TG]C / G]CA[G / T]CC[A / C]T[C / G]TG (SEQ ID NO: 125)

[0362] > pA (a 2) when positioned starting 17 to 25 or 35 to 47 nucleotides following the stop codon:

[0363] CCCCTCCCC[C / A]GTGCCT (SEQ ID NO: 126)

[0364] > pA 7 (SEQ ID NO: 98) CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACC CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGG AGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGATAAGATACATTGATGAGTTTGGA CAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTA TTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATT CATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACC TCTACAAATGTGGTA

[0365] > pA 8 (SEQ ID NO: 99) TAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCT TTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAC AAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTACTGTGCCTTCTAGTTGCCAG CCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCA CTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCT ATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGAGAATAG CAGGCAGGCTGGGGA

[0366] > pA 9 (SEQ ID NO: 100) CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACC CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGG

[0367] #15259787vlAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGAAATAAAAGATCTTTATTTTCATTA GATCTGTGTGTTGGTTTTTTGTGTG

[0368] > pA53 (SEQ ID NO: 101) TAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCT TTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAC AAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAATAAAAGATCTTTATTTTCA TTAGATCTGTGTGTTGGTTTTTTGTGTG

[0369] Aforementioned regulator / enhancer sequences generally produce an increase in gene expression when used with polyA sequences, however, when adjusted for construct size, which has a negative effect on potency, and even in several cases when not adjusted for construct size, the enhancer sequences may decrease the potency of expression when used with some polyA sequences. Therefore for the purpose of this invention, in an embodiment, a specific set of enhancer-pA combination can be used with subcutaneously administered, subcutaneously targeting, adipocyte targeting, or subcutaneously localizing gene therapies.

[0370] All categories evaluated enhancers produced an increased potency in subcutaneously administered gene therapies, except enhancers used with pA3 (AATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTG) (SEQ ID NO: 118), which was determined to be most effective when used with a 0-12 nucleotide spacer following the therapeutic gene of interest stop codon. Said sequence can be used, for example, when the total construct size becomes prohibitively large for the non-viral vector (such as for example above approximately 6000 nucleotides for lipid nanoparticle vectors that change in physicochemical properties at above approximately 6000 nucleotides of dsDNA cargo), or when vector minimization is required for efficient nuclear import regardless of the non-viral vector. In all other cases, enhancers showed a statistically significant increase in potency of non-viral vector delivered DNA in the subcutaneous tissues, with further potency enhancements derived from specific enhancer-pA pairings.

[0371] #15259787vlMoreover, regardless of the status of regulatory machinery expression in the cell, it was demonstrated that some combinations of enhancers and pA sequences produced high potency genetic cassettes, while others reduced the potency in proportion to their size, and yet others reduced potency in proportion greater than what would be expected from a simple size increase of the genetic cassette. As such, for the purposes of this invention, using genetic cassettes of approximately 500 to approximately 8000 bp or approximately 1200 to approximately 6000 bp for subcutaneous delivery with a non-viral delivery vector, in some embodiments, the following combinations of Reg-pA sequences are disclosed as optimally or maximally potency increasing (labelled as ‘Combination’ group):

[0372] > Combination A, Reg 1 / pA 4 (SEQ ID NO: 119) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGTAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGG AGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0373] > Combination B, Reg 1 / pAl (SEQ ID NO: 120) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC

[0374] #15259787vlCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCC TTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATT GCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGAC AGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0375] > Combination C, Reg 3 / pA4 (SEQ ID NO: 102) ATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCC CGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGA ACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGA CAATTCCGTGGTGCTGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAA CTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTT GTAACCATTATAAGCTGCAATAAACAAGTTTAAGATACATTGATGAGTTTGGACAAAC CACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTT TATTTGTAACCATTATAAGCTGCAATAAACAAGTT

[0376] > Combination D, Reg 1 / pA-Altl (SEQ ID NO: 103) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG

[0377] #15259787vlTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGCAGACATGAGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTG GCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCA TCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGG AGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACC AAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCA AGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGG CTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGT CTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTAC AGGCGTGAACCACTGCTCCCTTCCCTGTCCTT

[0378] > Combination E, Reg 1 / pA-Alt2 (SEQ ID NO: 104) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTT GCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGA CTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAA GTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGC AGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTG CCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTT TGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTA

[0379] #15259787vlATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACC ACTGCTCCCTTCCCTGTCCTT

[0380] > Combination F, Reg 3 / pA-Altl (SEQ ID NO: 105) ATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCC CGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGA ACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGA CAATTCCGTGGTGCTGCAGACATGAGGGTGGCATCCCTGTGACCCCTCCCCAGTGCC TCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTA AGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGT GGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTG GGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTG GGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATG ACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCA GGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCT GGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT

[0381] > Combination G, Reg 3 / pA-Alt2 (SEQ ID NO: 105) ATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTT GCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCC CGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGA ACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGA CAATTCCGTGGTGCTGCAGACATGAGGGTGGCATCCCTGTGACCCCTCCCCAGTGCC TCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTA AGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGT GGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTG GGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTG GGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATG ACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCA

[0382] #15259787vlGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCT GGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT

[0383] Following adjustment for size, combination of Reg 1 can be beneficial with pA4 and pAl, Reg 3 with pA4, but not pAl and pA3. Combination of Reg 2 with pAl provides a negative size corrected effect, so does Reg 3 with pAl and Reg 3 with pA3, in some embodiments. As such, non-virally delivered gene therapies with adipocyte targeting or subcutaneous localization of DNA can benefit from the utilization of the following sequences 0 to 12 nucleotides following the stop codon, with the optional use of two sequential stop codons, and with a spacer of 0 to 12 nucleotides between the regulatory and pA sequence.

[0384] Combining said sequences with one or more optimal spacers results in the following full combination sequences, which may also optionally be used in the non-virally delivered, subcutaneously administered, subcutaneously localization, subcutaneously targeted, or adipocyte targeted gene therapies (labelled ‘Full Combination’ below). Said full combinations may or may not be potency maximizing, but have all demonstrated functionality in adipocytes in vivo and may be used when higher or lower potency of expression is required and may be positioned 0 to 12 nucleotides following the stop codon of the therapeutic transgene:

[0385] > Full Combination A, Reg 1 / pA 4 (SEQ ID NO: 119) AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGTAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA

[0386] #15259787vlAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGG AGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0387] > Full Combination B, Reg 1 / pA 1 (SEQ ID NO: 106) TGAAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGT TGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTC CCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGA GTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAAC CCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTC CCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAG GGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCT TTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTA CGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTG CGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCG CCTCCCCGCCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTG CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAA TTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGA CAGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0388] > Full Combination C, Reg 2 / pA 1 (SEQ ID NO: 107) TGAGAGCATCTTACCGCCATTTATACCCATATTTGTTCTGTTTTTCTTGATTTGGGTATA CATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGT AATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTAT TTACGCTCTGTTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGA TATTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTAT CTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTG TCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGT TTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTG GGACTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGC CCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTTGTCCTGC

[0389] #15259787vlTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCC TGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTG TCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGA GGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0390] > Full Combination D, Reg 3 / pA 4 (SEQ ID NO: 108) TGAATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTAT GTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCT TCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCG GAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACT GACAATTCCGTGGTGCTGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCAC AACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTAT TTGTAACCATTATAAGCTGCAATAAACAAGTTTAAGATACATTGATGAGTTTGGACAA ACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTG CTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTT

[0391] > Full Combination E, Reg 3 / pA 1 (SEQ ID NO: 109) TGAATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTAT GTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCT TCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCG GAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACT GACAATTCCGTGGTGCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAAT GAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGG GGCAGGACAGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0392] > Full Combination F, Reg 2 / pA 4 (SEQ ID NO: 110) TGAGAGCATCTTACCGCCATTTATACCCATATTTGTTCTGTTTTTCTTGATTTGGGTATA CATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGT AATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAACTTTCCCGTTAT TTACGCTCTGTTCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGA

[0393] #15259787vlTATTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTAT CTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTG TCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGT TTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTG GGACTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGC CCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTTGTCCTGT AAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTT TATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACA AGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0394] > Full Combination G, Reg 3 / pA 3 (SEQ ID NO: 111) TGAATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTAT GTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCT TCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCG GAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACT GACAATTCCGTGGTGAATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTT GTGTG

[0395] > Full Combination H, pA 1 (SEQ ID NO: 112) TGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTG ACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGC ATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGG GGGAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA

[0396] > Full Combination I, pA 2 (SEQ ID NO: 113) TGAGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCC ACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTA GGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTT GGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGT GGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCT

[0397] #15259787vlCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACT GCTCCCTTCCCTGTCCTT

[0398] > Full Combination J, pA 3 (SEQ ID NO: 114) TGAAATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTG

[0399] > Full Combination K, pA4 (SEQ ID NO: 115) TGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAAT GCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATA AACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTG GGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0400] > Full Combination L, pA 5 (o) (SEQ ID NO: 116) TGACAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGT GAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAA GCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGG GGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA

[0401] > Full Combination M, pA 5 (SEQ ID NO: 96) GATCCACTCCTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATG CCCTGGCTCACAAATACCACTGAGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAA TAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCA TTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCCATATGCTGG CTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGAAACAGCCCCCTGC TGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTTTATATTTTG TTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTCTCTTArGGAGATCCCTCGACGCGC

[0402] #15259787vlIn accordance with the above, the present invention provides, at least in part, therapeutic gene therapy formulations designed for the treatment of a wide range of human and veterinary pathologies, and more specifically the use of potency, efficacy, therapeutic index, or productivity related genetic elements. The present invention can generally enhance formulations that are engineered to achieve subcutaneous targeting or localization of DNA delivery vectors, allowing for the localized expression and systemic secretion of therapeutic proteins and peptides with sufficient productivity to mediate therapeutic effect.

[0403] The DNA constructs described herein can be formulated with at least one subcutaneous-cell-type-specific enhancer sequence or motif, which is delivered in cis with the therapeutic transgene and is selected from a class of enhancer, regulatory, and / or polyadenylation sequences, and optionally at least one enhancer sequence or motif from a class of enhance or regulator sequences. These sequences are positioned downstream of the therapeutic transgene with optimized spacer sequences to enhance expression. The positioning is typically within 0-12 nucleotides downstream of the stop codon, but certain consensus sequences may be positioned further downstream as distal enhancers.

[0404] Abroad array of therapeutic proteins or peptides is contemplated, including but not limited to those derived from:

[0405] • Incretins

[0406] • Antibodies and antibody fragments

[0407] • Or generally mammalian or human secreted proteins

[0408] • Fusion proteins (e.g., albumin-fusion, Fc-fusion, globulin-binding peptide fusions)

[0409] • Growth factor families such as fibroblast growth factors (FGF), transforming growth factor-beta (TGF-0), epidermal growth factors (EGF), vascular endothelial growth factors (VEGF), insulin-like growth factors (IGF), hepatocyte growth factors (HGF), bone morphogenetic proteins (BMP), platelet-derived growth factors (PDGF), growth differentiation factors (GDF), and others

[0410] #15259787vl• Cytokine and cytokine receptor families, including interleukins, interferons, chemokines, colony-stimulating factors (CSFs), and their respective antagonists

[0411] • Hormone-like peptides such as GLP-1, glucagon, amylin, gastric inhibitor peptides, prolactin, and growth hormone derivatives

[0412] • Immunomodulatory peptides and proteins such as defensins, cathelicidins, galectins, serpins, lectins, sFRPs, and RELMs

[0413] The DNA constructs may take various forms, including circular or linear, single- or doublestranded, covalently closed, chemically modified DNA, DNA / RNA hybrids, and chemically conjugated forms with peptides or small molecules.

[0414] The delivery vectors can be non-viral, including lipid nanoparticles, liposomes, lipid micelles, liposomal bilayers, nanoemulsion droplets, polyelectrolyte complexes, polymeric nanoparticles, dendrimers, bioresorbable polymers, exosomes, solid lipid nanoparticles, silica / metallic / ceramic nanoparticles, micelles, and DNA nanostructures. These non-viral vectors may be further functionalized with ligands such as peptides, polymers, sugars, antibodies, or proteins.

[0415] Viral vectors are also proposed in accordance with the present invention, including adenovirus, lentivirus, retrovirus, herpes simplex virus, cytomegalovirus, vaccinia or Modified Vaccinia Ankara (MVA), and others. These may be selected from a broad class of viruses such as Alphaherpesvirus, Alpharetrovirus, Betacoronavirus, Filovirus, Hepatitis viruses (A-E), HIV, HPV, Influenza, SARS-CoV-2, and many others. These viral vectors contain a nucleic acid encoding a therapeutic transgene and can be suitable for subcutaneous delivery.

[0416] Administration routes proposed for the purposes of this invention include subcutaneous injection or infusion, and intravenous delivery of subcutaneously targeting vectors. Devices for delivery may include autoinjectors, pen injectors, syringes, microneedles, jet injectors, or patch-based systems.

[0417] Enhancer sequences of the Reg and pA classes are described with specific SEQ ID numbers (e.g., Reg 1-110 (SEQ ID NOs: 1-60), pA 1-53 (SEQ ID NOs: 61-101, 118, 121, 122)). These may be used individually or in combination, positioned 0-12 nucleotides downstream of the transgene's stop codon or downstream of other enhancer elements. Variants with >50% coverage and >72%

[0418] #15259787vlidentity to defined Reg sequences are also within scope. Additional enhancer sequences can be derived via deletion of motifs (e.g., EE3 (SEQ ID NO: 51)).

[0419] Spacer sequences may consist of A, C, T, or G alone or in combination, forming sequences of CI-12 nucleotides in length. Examples include TAA, TAG, TGA, or longer sequences such as CTG, CTGCAG, CTGCAGACA, or CTGCAGACATGA (SEQ ID NO: 117). These may follow either the therapeutic transgene stop codon or the Reg element.

[0420] The pathologies targeted by formulations provided herein include, but are not limited to:

[0421] • Metabolic and endocrine diseases such as type 1 and 2 diabetes, obesity, hyperlipidemia, hypothyroidism

[0422] • Cardiovascular conditions including hypertension, coronary artery disease, heart failure • Respiratory diseases such as COPD, asthma, pulmonary fibrosis

[0423] • Neurological and psychiatric disorders including Alzheimer’s, Parkinson’s, epilepsy, depression, schizophrenia

[0424] • Autoimmune and monogenic conditions

[0425] • Infectious diseases such as HIV, tuberculosis, malaria, hepatitis, and COVID- 19

[0426] • Oncologic indications such as breast, prostate, colorectal, and pancreatic cancer

[0427] • Musculoskeletal and dermatologic disorders such as rheumatoid arthritis, psoriasis, and acne

[0428] • Gastrointestinal and reproductive diseases such as IBD, endometriosis, and uterine fibroids • Or other human or veterinary pathologies.

[0429] The disclosed gene therapy formulations allow for improved expression control through cell-type-specific or local-tissue-specific enhancer motifs and optimized spacer sequences, enabling effective and durable protein expression in target tissues. This system is particularly effective for secreted proteins requiring sustained systemic therapeutic levels following localized DNA delivery.

[0430] #15259787vlThe aforedescribed genetic elements are most optimally utilized with non-viral deliver vectors. Some examples of said non-viral delivery vectors include: Lipid nanoparticles (LNPs), liposomes, lipid micelles, carbon nanotubes, nano emulsion droplet, lipid bilayer sheet, polyelectrolytic complex, polymeric nanoparticles, dendrimers, polyethyleneimine (PEI)-based complexes, bioresorbable polymeric nanoparticles such as poly(lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles, exosomes, micelles, cell-penetrating peptides, cationic emulsions, calcium phosphate nanoparticles, silica nanoparticles, metallic nanoparticles, ceramic nanoparticles, DNA nanostructures, and naked plasmid DNA, or combinations or functionalized derivatives thereof.

[0431] Lipid nanoparticles used for the delivery of genetic cassettes that incorporate sequences described in the present invention can contain no ionizable lipids, multiple ionizable lipids, phospholipids, amphiphilic lipids, conjugated lipids, peptides, proteins, monoclonal antibodies, antibody fragments, DNA, RNA, sterols, structural lipids, polymers, oligomers, polysaccharides, monosaccharides, disaccharides, or surfactants, buffers, stabilizers, antioxidants, or more specifically one or more of bile acids, sphingomyelins, sphingoid bases, gangliosides, glycosphingolipids, ceramides, triacylglycerols, diacylglycerols, monoacylglycerols, isoprenoids, polyprenols, saccharolipids, glycerophosphocholines, glycerophosphoethanolamines, glycerophosphoserines, glycerophosphoglycerols, glycerophosphoinositols, glycerophosphophates, cardiolipins, oxidized glycerophospholipids, thromboxanes, prostaglandins, octadecanoids, lipoxins, leukotrienes, isoprostanes, eicosandoids, fatty esters, fatty ethers, fatty ether-esters, fatty amides, fatty alcohols, fatty aldehydes, fatty acids and conjugates thereof, docosanoids, C2 Ceramide- 1 -phosphate, (2S,3R,4E)-2-Amino-4-tetradecene-l,3-diol, Azido-erythro-sphingosine, Sphingosine- 1 -phosphate (dl6: 1), Sphingosine- 1 -phosphate (dl7: 1), Sphingosine- 1 -phosphate (dl 8: 1), N-Butyroyl Phytosphingosine, N-Boc-erythro-sphingosine, D-erythro Lysosphingomyelin (dl 8: 1), C24: 1 Ceramide, C2 to C22 Dihydroceramide, Omega-azido-C6 Ceramide, C16 Sphingomyelin (dl8: 1 / 16:0), 1,2-Dioleoyl-sn-glycerophosphoethanolamine (DOPE), DOPC, ALC-0159, Stearic acid, Nonadecanoic Acid, Arachidic acid, Heneicosanoic acid, Docosanoic acid, Tricosanoic acid, Tetracosanoic acid, 10-Undecenoic acid, 11 -Dodecenoic acid, 12-Tridecenoic Acid, Myristelaidic acid, 14-Pentadecenoic acid, 10(Z)-Pentadecenoic acid, 10-Trans-pentadecenoic acid, Palmitelaidic Acid, cis-10-Heptadecenoic acid, Trans- 10-

[0432] #15259787vlHeptadecenoic Acid, Cis-Vaccenic acid, Trans-Vaccenic acid, Elaidic acid, Ricinoleic acid, Ricinelaidic acid, Petroselinic acid, Trans-Petroselinic Acid, lOZ-Nonadecenoic acid, 10(E)-Nonadecenoic Acid, Delta 7 cis nonadecenoic acid, 7-Trans-Nonadecenoic, (Z)-Icos-ll-enoic acid, trans- 11-Eicosenoic acid, 8(z)-eicosenoic acid, cis-5-Eicosenoic acid, 12(Z)-Heneicosenoic acid, Erucic acid, 13(E)-Docosenoic Acid, (14Z)-14-tricosenoic acid, Nervonic acid, Linolelaidic acid, 9Z,llZ-octadecadienoicacid, (10z,12z)-octadeca-10,12-dienoic acid, (10Z,13Z)-10,13-nonadecadienoic acid, ll(Z)14(Z)-Eicosadienoic Acid, 12(Z)15(Z)-Heneicosadienoic Acid, 13,16-Docosadienoic acid, (13Z,16Z), alpha-Linolenic acid, Gamma-Linolenic acid, ll(Z)14(Z)17(Z)-Eicosatrienoic Acid, Docosatrienoic Acid, Adrenic Acid, Eicosapentaenoic Acid, Docosapentaenoic Acid, all-cis-47101316-Docosapentaenoic Acid, 306Oi9-cis2, BAMEA-O16B, Al-28, C13-113-tri-tail, C12-113, C13-113-tetra-tail, 1014, C3-K2-E14, OC2-K3-E10, 98N12-5, G0-C14, C12-SPM, C14-SPM, cKK-E12, OF-02, OF-C4-Deg-Lin, 246C10, IC8, C12-200, BP Lipid 432, BP Lipid 103, BP Lipid 124, Lipid A4, C14-4, PPZ-A10, TT3, FTT5, AA-T3A-C12, MVL5, Cl 3-112-tri-tail, C13-112-tetra-tail, BP Lipid 375, BP Lipid 374, BP Lipid 373, BP Lipid 372, 9A1P9, iPhos-lipidl, iPhos-lipid3, iPhos-lipid4, Dihexadecyl Phosphate, Lipid Catechol, DLPA, DMPA, DPPA, DSPA, 18:1 PA, l,2-Dioleoyl-sn-glycero-3-PA (ammonium salt), 1-Palmitoyl-2-Oleoyl-sn-glycero-3-PA, 14:0 Lyso PE, 16:0 Lyso PE, 18:0 Lyso PE, 18:1 Lyso PE, 1.2-Didecanoyl-Sn-Glycero-3-Phosphoethanolamine, 1 ,2-Dilauroyl-sn-glycero-3-PE, DMPE, 1.2-Dipalmitoyl-sn-glycero-3-PE, 1,3-DPPE, 4ME 16:0 PE, POPE, l-Stearoyl-2-Oleoyl-sn-glycero-3-PE, l-Stearoyl-2-Linoleoyl-Sn-Glycero-3-Phosphoethanolamine, 14:0 Lyso PC, 16:0 Lyso PC, 18:0 Lyso PC, l-Palmitoyl-d9-2-hydroxy-sn-glycero-3-PC, l-Palmitoyl-d3-2-hydroxy-sn-glycero-3-PC, 18:1 Lyso PC, rac-3-Hexadecanamido-2-methoxypropan-l-ol Phosphocholine Monohydrate, 2-Arachidonoyl-sn-glycero-3-phosphocholine (>90%), DHPC, 08:0 PC, DDPC, DLPC, DMPC, MPPC, MSPC, PLPC, PMPC, DPPC, l-Palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine, 17:0 PC, SMPC, SPPC, Distearoylphosphatidylcholine (DSPC), 19:0 PC, DAPC, 16:0 Diether PC, PDME, 4ME 16:0 PC, DEPC, l-Oleoyl-2-Palmitoyl-sn-glycero-3-PC, POPC, SOPC, PTPC, SDPC, 22:6 (Cis) PC, l-Palmitoyl-2-(Propargylacetyl)-Sn-Glycero-3-Phosphocholine, SM-102 N-oxide, ALC-0315 N-oxide, Hexadecanedioic Acid Mono-L-carnitine Ester Chloride, Octadecanedioic Acid Mono-L-carnitine Ester Chloride, TAP (14:0), 16:0 TAP, 18:0 TAP, DGTS (l,2-dipalmitoyl-sn-glycero-3-O-4'-[N,N,N-trimethyl]-homoserine), 18:1 TAP (l,2-Dioleoyl-3-trimethylammonium propane or DOTAP, MS Salt), DC-6-14, 12:0 EPC (Cl Salt),

[0433] #15259787vl14:0 EPC (Cl Salt), 16:0 EPC (Cl Salt), 18:0 EPC (Cl Salt), 14:1 EPC (Tf Salt), 18:1 EPC (Cl Salt), 16:0-18:1 EPC (Cl Salt), l-Palmitoyl-2-arachidoyllecithin, 18:0 DDAB, DOTAP, DOTMA, DODAC, DORI, DOBAQ, DOSPA HC1 salt, 113-O12B, 113-O16B, 14:0 DAP, 16:0 DAP, 304013, 306-N16B, 306-O12B, 306-O12B-3, 306OH0, 4A3-SC8, 503013, 80-O16B, 93-0170, 93-O17S, , A12-Iso5-2DC18, A18-Iso5-2DC18, AA3-DLin, ALC-0315, ATX-001, ATX-100, CKK-E15, CL1, DLin-DMA, DLin-MC3-DMA, DLin-KC2-DMA, D-Lin-MC2-DMA, D-Lin-MC3-DMA, D-Lin-MC4-DMA, DODAP (18:1), DODMA, DOG-IM4, IAJD249, IAJD93, L13, L14, L15, L16, L2, L3, L319, L9, Lipid 10, Lipid 14, Lipid 16, Lipid 2, Lipid 23, Lipid 29, Lipid 5, Lipid 8, Lipid A6, Lipid A9, Lipid AX4, Lipid C24, Lipid III-45, Lipid R6, LP01, NT1-O14B, OF-Deg-Lin, RCB-4-8, RM 133-3, RM 137-15, SM-102, SSPalmM, SSPalmO-Phe, TCL053, YSK05, 11-A-M, 1-A-N, Cholesterol, Campesterol, Beta-Sitosterol, Brassicasterol, Ergosterol, DHE (Dehydroergosterol), Stigmasterol, Fucosterol, DC-Cholesterol HC1, OH-Chol, OH-C-Chol, HAPC-Chol, MHAPC-Chol, DMHAPC-Chol, DMPAC-Chol, Cholesteryl chloroformate, GL67, Cholesteryl isovalerate, Cholesteryl Acetate, Cholesterol Butyrate, Cholesterol valerate, Cholesterol Hexanoate, Cholesteryl heptanoate, Cholesteryl caprylate, Cholesterol Pelargonate, Cholesterol decanoate, Cholesteryl undecanoate, Cholesterol Laurate, Cholesteryl Tridecanoate, Cholesteryl Myristate, Cholesteryl Pentadecanoate, Cholesteryl Palmitate, Cholesteryl Heptadecanoate, Cholesteryl Stearate, Cholesteryl nonadecanoate, Cholesteryl Arachidate, Cholesteryl Heneicosanoate, Cholesteryl Behenate, Cholesteryl Tricosanoate, Cholesteryl Lignocerate, Cholesteryl Myristoleate, Cholesteryl Palmitoleate, Cholesteryl Oleate, Cholesteryl 11-Eicosenoate, Cholesteryl Erucate, Cholesteryl Nerv onate, Cholesteryl Petroselinate, Cholesteryl Vaccenate (CIS), Cholesteryl Linoleate, Cholesteryl 11-14 Eicosadienoate, Cholesteryl Alpha Linolenate, Cholesteryl Gamma Linolenate, Cholesteryl 11-14-17 Eicosatrienoate, Cholesteryl Arachidonate, Cholesteryl Eicosapentaenoate, Cholesteryl Docosapentaenoate, LC10, Cholesteryl Hemisuccinate, (3B,5B)-3-Hydroxycholan-24-oic acid, Alkyne Cholesterol, 27-Alkyne Cholesterol, E-Cholesterol Alkyne, Biotin-Cholestero, Glucosamine Cholesterol, Cholesterol-Doxorubicin, Cholesterol-Undecanoate-Glucose Conjugate, Cho-es-Lys, Dios-Arg (trifluoroacetate salt), 2H-Cho-Arg (trifluoroacetate salt), Cho-Arg (trifluoroacetate salt), or their derivative.

[0434] #15259787vlMoreover, the aforedescribed genetic elements may be optimally utilized with viral vectors or recombinant viral vectors, or combinations of non-viral and viral vectors within one or more formulations. Such viral vectors include adenovirus, adeno-associated virus (AAV), Alphacoronavirus, Alphaherpesvirus, Alpharetrovirus, Alphavirus, Anellovirus, Astrovirus, Avulavirus, Betacoronavirus, Betaherpesvirus, Betaretrovirus, Betaretrovirus, Bornavirus, Bunyavirus, Calicivirus, Circovirus, Coxsackievirus, Cytomegalovirus, Deltacoronavirus, Deltaretrovirus, Dengue virus, Ebolavirus, Enterovirus, Filovirus, Flavivirus, Gammacoronavirus, Gammaherpesvirus, Hantavirus, Hepacivirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus, Human immunodeficiency virus (HIV), Human papillomavirus (HPV), Influenza virus, Lentivirus, Lyssavirus, Marburgvirus, Measles virus, Metapneumovirus, Mumps virus, Norovirus, Orthohantavirus, Orthomyxovirus, Parainfluenza virus, Parechovirus, Picornavirus, Poliovirus, Polyomavirus, Rabies virus, Reovirus, Respiratory syncytial virus (RSV), Retrovirus, Rhinovirus, Rotavirus, Rubivirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Simian foamy virus, Tenuivirus, Togavirus, Varicella-zoster virus, Variola virus (Smallpox virus), Vesiculovirus, West Nile virus, Yellow fever virus, Zika virus.

[0435] Genetic elements and the derived therapeutic formulations can be utilized for subcutaneous, intramuscular, intravenous, intrathecal, intracerebroventricular, intradermal, topical, intraperitoneal, intra-arterial, intrapancreatic, epidural, intra-articular, intraosseous, intracardiac, or intravitreal administration. Alternatively, the formulations may be administered locally via an injection, preferably into a local fat pad or tissue intended to be targeted by the therapeutic treatment or tissue intended to be used as the therapeutic producing tissue of interest.

[0436] It should be understood that within the scope of this invention the formulation, materials, active agents, active ingredients, moieties, small molecules, drug product compositions, or methods of use may be varied by one skilled in the art, to the extent that the structures described herewithin perform the desired function and remain within the scope of the present invention. Various parts, components or characteristics may be used in combination, with or without modification by someone skilled in the art to achieve the desired functionality of the aforedescribed formulation.

[0437] #15259787vlMoreover, all individual features and methods of use described herein, and each and every combination of two or more of such features and methods of use, are included within the scope of the present invention provided that these features and methods of use in such a combination are not mutually inconsistent. It is understood that certain portions or combinations of such portions can be varied by someone trained in the art while still achieving the main goal of the invention. Finally, it is understood that the specific ranges provided in the current invention are not restrictive and are for example purposes only, values outside of the specified ranges may be used to achieve the goal of the invention without modification to the proposed mechanistic principles.

[0438] EXAMPLES

[0439] Example 1

[0440] A gene therapy treatment for type 2 diabetes and obesity is developed by combining a lipid nanoparticle delivery vector with a double stranded circular DNA cassette encoding a GIP peptide fused with an Fc protein fragment. The genetic cassette is encapsulated in a lipid nanoparticle vector comprised of ALC-0315, Cholesterol, DMG-PEG(2000), DSPC, and hydroxychloroquine at an N / P ratio of 433 as follows:

[0441] Component Type Molar Ratio Ionization pKas

[0442] Ionizable structural

[0443] Hydroxychloroquine 142 <4.0, 8.3, and 9.7 component

[0444] Ionizable lipid

[0445] ALC-0315 7.00 6.1

[0446] component

[0447]

[0448] #15259787vlStructural and effector

[0449] Cholesterol 5.39 N / A component

[0450] Amphiphilic outer layer

[0451] DMG-PEG(IOOO) 0.21 N / A forming component

[0452] Phospholipid structural

[0453] DSPC 1.40 N / A component

[0454] N to P ratio n / a 433 N / A

[0455]

[0456] The genetic cassette includes a promoter driving the GIP-Fc fusion coding region, which ends in a TAA stop codon. The TAA stop codon is followed by a TGA spacer, after which the following enhancer and pA sequence combination is introduced:

[0457] AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGTAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC

[0458] #15259787vlTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGG AGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA (SEQ ID NO: 119)

[0459] The sequence is introduced immediately downstream of the TGA spacer and is followed downstream by the minimal plasmid backbone.

[0460] Example 2

[0461] A gene therapy treatment for type 2 diabetes and obesity is developed by combining a polymeric nanoparticle delivery vector with a double stranded covalently closed DNA cassette encoding a GLP-l-Fc fusion protein. The GLP-l-Fc fusion protein is terminated with a TGA codon, which is immediately followed by the subsequent proximal enhancer / terminator sequence:

[0462] AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCG TATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTT GTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCC CACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCC CTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGG GCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGCCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCC TTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATT GCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGAC AGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA (SEQ ID NO: 120)

[0463] #15259787vlExample 3

[0464] A gene therapy treatment for sarcopenia combines a liposomal delivery vector and a double stranded circular DNA cassette encoding a myostatin inhibitor. The coding region of the transgene is terminated with a TAA stop codon, which is followed by a 3 nucleotide spacer. The 3 nucleotide spacer is followed immediately downstream by the adipocyte expression enhancing sequence: GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACT CCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGT GTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGG AAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGC ACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAG CCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTT TTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAG GTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTC CCTTCCCTGTCCTT (SEQ ID NO: 121)

[0465] Example 4

[0466] A gene therapy treatment for type 1 diabetes is disclosed combining a lipid nanoparticle vector encapsulating a Furin-cleavable insulin encoding genetic cassette for basal insulin gene expression.

[0467] The therapeutic transgene is terminated with a TAA stop codon, which is followed by a proximal enhancer element of up to 371 nt. The proximal enhancer element is then immediately followed by SEQ ID NO: 11:

[0468] GTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT CCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACG TCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCG GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC TCCCCGC

[0469] #15259787vlWhich is immediately followed by pA 1 :

[0470] CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACC CTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATT GTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGG AGGATTGGGAAGAGAATAGCAGGCAGGCTGGGGA (SEQ ID NO : 122)

[0471] Following pA 1, the double stranded circular DNA contains the miniaturized plasmid backbone sequence, followed by the promoter driving expression of the therapeutic transgene.

[0472] Example 5

[0473] A therapeutic gene therapy treatment for the treatment of Metabolic dysfunction-associated steatotic liver disease is developed by combining a lipid nanoparticle formulation with a genetic cassette encoding the human FGF21 transgene coding region.

[0474] The stop codon for the coding region of the FGF21 transgene is TAA, which is followed by a TGA secondary stop codon and a 9 nt spacer. The spacer is subsequently followed by a proximal enhancer element and then immediately by pA 2, as follows:

[0475] GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACT CCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGT GTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGG AAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGC ACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAG CCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTT TTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAG GTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTC CCTTCCCTGTCCTT (SEQ ID NO: 121)

[0476] Example 6 - Enhancement of Expression Using Regulatory Sequence Reg 1 and Polyadenylation Sequence pA 4

[0477] #15259787vlMaterials and Methods

[0478] A gene therapy construct comprising a nucleic acid encoding an intracellular reporter protein was generated as a control construct. The construct included a promoter, coding sequence, and a reference polyadenylation sequence.

[0479] A modified construct was generated that was identical to the control construct except for the inclusion of:

[0480] • a regulatory sequence corresponding to SEQ ID NO: Reg 1, operably linked downstream of the coding sequence; and

[0481] • a polyadenylation sequence corresponding to SEQ ID NO: pA 4, operably linked to the regulatory sequence.

[0482] All constructs were otherwise identical, including promoter, coding sequence, backbone, and overall architecture. The constructs were formulated in a non-viral delivery vector and administered via subcutaneous injection to test subjects. Expression was measured in vivo using whole-body imaging, and total flux (photons / second) was quantified.

[0483] Results

[0484] The control construct exhibited an expression level of approximately:

[0485] • 9.56 x 107photons / second (p / s).

[0486] The construct comprising Reg 1 and pA 4 exhibited an expression level of approximately:

[0487] • 4.38 x 108photons / second (p / s).

[0488] This represents an approximately:

[0489] • 4.6-fold increase in expression relative to the control construct.

[0490] The inclusion of regulatory sequence Reg 1 in combination with polyadenylation sequence pA 4 resulted in a substantial increase in expression following subcutaneous administration using a non-

[0491] #15259787vlviral delivery vector. This result demonstrates that the combination of regulatory and poly adenylation sequences enhances expression relative to a construct lacking such sequences.

[0492] Example 7 - Enhancement of Expression Using Regulatory Sequence Reg 1 and Polyadenylation Sequence pA 1

[0493] Materials and Methods

[0494] A gene therapy construct comprising a nucleic acid encoding an intracellular reporter protein was generated as a control construct, comprising a promoter, coding sequence, and reference poly adenylation sequence.

[0495] A modified construct was generated that was identical to the control construct except for the inclusion of:

[0496] • a regulatory sequence corresponding to SEQ ID NO: Reg 1, operably linked downstream of the coding sequence; and

[0497] • a polyadenylation sequence corresponding to SEQ ID NO: pA 1, operably linked to the regulatory sequence.

[0498] All constructs were otherwise identical in sequence composition and structure. The constructs were formulated in a non-viral delivery vector and administered via subcutaneous injection. Expression was measured in vivo by quantifying total flux (photons / second).

[0499] Results

[0500] The control construct exhibited an expression level of approximately:

[0501] • 9.56 x 107photons / second (p / s).

[0502] The construct comprising Reg 1 and pA 1 exhibited an expression level of approximately:

[0503] • 4.35 x 108photons / second (p / s).

[0504] This corresponds to an approximately:

[0505] #15259787vl• 4.5-fold increase in expression relative to the control construct.

[0506] The combination of regulatory sequence Reg 1 and polyadenylation sequence pA 1 significantly enhances expression following subcutaneous administration using a non-viral delivery system. These results further support that the combined inclusion of regulatory and polyadenylation sequences improves expression relative to constructs lacking such elements.

[0507] Example 8

[0508] Effect of Construct Size on Expression Following Subcutaneous Administration

[0509] In accordance with the present invention, the relationship between genetic cassette size and expression potency was systematically evaluated following subcutaneous administration of non-viral gene therapy constructs. To isolate the effect of construct size independent of functional regulatory activity, a series of constructs were generated comprising non-functional spacer sequences, which do not contribute to transcriptional, post-transcriptional, or translational enhancement. These spacer sequences were introduced to increase the total size of the genetic cassette without altering the coding sequence or functional regulatory elements.

[0510] The genetic constructs evaluated comprised double-stranded circular DNA cassettes having total lengths ranging from approximately 2208 nucleotides to 7356 nucleotides.

[0511] External Spacer Constructs

[0512] In a first set of experiments, non-functional spacer sequences were added externally, defined as insertion downstream of the poly adenylation sequence at the 3' end of the cassette. These external spacer constructs increased cassette size from approximately 2208 nucleotides to 7356 nucleotides.

[0513] Internal Spacer Constructs

[0514] #15259787vlIn a second set of experiments, non-functional spacer sequences were added internally, defined as insertion upstream of the poly adenylation sequence and downstream of the coding sequence. These internal spacer constructs increased cassette size from approximately 2208 nucleotides to 7328 nucleotides (FIG.8).

[0515] Observed Size-Dependent Reduction in Expression

[0516] Across both external and internal spacer configurations, a consistent and substantial reduction in expression potency was observed as a function of increasing cassette size. Expression levels were measured as total flux, and constructs exhibited a decrease in expression from approximately:

[0517] • 1 x 109photons / second (p / s) at smaller cassette sizes (-2208 nt),

[0518] to

[0519] • approximately 8 x 105photons / second (p / s) at larger cassette sizes (-7300 nt range). This reduction was observed regardless of whether spacer sequences were placed internally or externally, demonstrating that: the decrease in expression is driven primarily by overall cassette size, rather than positional effects of non-functional sequence insertion.

[0520] These data establish a negative correlation between genetic cassette size and expression potency in subcutaneously administered, non-viral gene therapy constructs.

[0521] Regression Analysis of Size-Potency Relationship

[0522] The observed relationship between cassette size and expression defines a predictable regression curve, wherein increasing cassette length results in a progressive decline in expression output. This regression provides a baseline expectation for expression levels as a function of construct size in the absence of functional regulatory enhancement.

[0523] Functional Override by Regulatory and Poly adenylation Sequences

[0524] #15259787vlIn contrast to constructs containing only non-functional spacer sequences, it was demonstrated that inclusion of specific regulatory sequences in combination with subcutaneously functional polyadenylation sequences results in a functional override of the size-dependent reduction in expression.

[0525] Specifically, constructs comprising:

[0526] • at least one regulatory (enhancer) sequence, and

[0527] • at least one polyadenylation sequence that increases expression in subcutaneous tissue consistently exhibited expression levels that were greater than those predicted by the sizedependent regression curve. In multiple tested configurations, such constructs demonstrated expression levels that exceeded those of size-matched control constructs lacking such regulatory elements (FIG. 15).

[0528] Synergistic Effect of Regulatory Sequence and Poly adenylation Sequence

[0529] Importantly, it was further observed that:

[0530] • inclusion of the regulatory sequence alone, or

[0531] • inclusion of the polyadenylation sequence alone resulted in partial or limited improvements in expression.

[0532] However, the combined inclusion of both elements resulted in an increase in expression that exceeded the effect of either component alone.

[0533] This demonstrates a synergistic interaction between regulatory sequences and polyadenylation sequences in the context of subcutaneous gene expression.

[0534] The findings establish that:

[0535] 1. Increasing genetic cassette size in non-viral gene therapy constructs results in a substantial and predictable decrease in expression following subcutaneous administration;

[0536] #15259787vl2. This size-dependent reduction occurs regardless of whether additional sequence is inserted internally or externally relative to the polyadenylation sequence; and

[0537] 3. The inclusion of specific regulatory sequences in combination with subcutaneously functional polyadenylation sequences overcomes this limitation, resulting in expression levels that exceed those predicted based on construct size alone.

[0538] Accordingly, the present invention provides a solution to the problem of reduced potency in larger non-viral gene therapy constructs by enabling enhanced expression in subcutaneous tissues despite increased genetic cassette size.

[0539] Effect of Construct Size on Localization of Expression

[0540] In addition to evaluating the relationship between genetic cassette size and expression potency, the effect of construct size on the localization of gene expression following subcutaneous administration was also investigated.

[0541] It was observed that construct size influences not only the magnitude of expression but also the distribution of expression relative to the site of administration. Specifically, constructs having larger cassette sizes exhibited reduced localization of expression, while smaller constructs demonstrated substantially increased localization to the site of injection.

[0542] Across constructs evaluated, localization of expression was observed to increase from approximately:

[0543] • 30% localization for larger genetic cassettes (greater than approximately 7000 nucleotides),

[0544] to

[0545] • greater than 91 % localization for smaller genetic cassettes (approximately 2200 nucleotides).

[0546] Localization was determined based on the proportion of total expression signal detected at or proximal to the subcutaneous injection site relative to total systemic signal.

[0547] #15259787vlSafety and Tolerability Advantages of Localized Expression

[0548] The observed increase in localization with decreasing construct size has important implications for the safety and tolerability of subcutaneously administered gene therapies.

[0549] In particular, increased localization of expression:

[0550] • reduces exposure of non-target tissues to the expressed therapeutic protein;

[0551] • limits systemic distribution of the expressed product; and

[0552] • reduces the risk of off-target biological effects and associated toxicities.

[0553] Accordingly, gene therapy constructs that promote localized expression in subcutaneous tissue are preferred from a therapeutic index and safety perspective.

[0554] Effect of Regulatory and Poly adenylation Sequences on Biodistribution

[0555] Whether inclusion of the disclosed regulatory sequences and subcutaneously functional polyadenylation sequences alters the biodistribution of expression or the localization of the delivered DNA was further evaluated.

[0556] The studies demonstrated that inclusion of the regulatory sequence and polyadenylation sequence does not statistically alter the biodistribution of the expressed intracellular reporter. More specifically, constructs comprising the regulatory and polyadenylation sequences exhibited substantially similar localization profiles compared to control constructs lacking such sequences (FIG. 16)

[0557] Decoupling of Potency and Localization

[0558] Findings indicate that the disclosed regulatory and poly adenylation sequences:

[0559] • increase expression potency;

[0560] #15259787vl• overcome size-dependent reductions in expression;

[0561] while simultaneously:

[0562] • not altering the localization of expression, and

[0563] • not altering the biodistribution of the delivered DNA.

[0564] Thus, increased expression without increased systemic exposure can be provided, which is a highly desirable and non-obvious characteristic in gene therapy design.

[0565] Taken together, it has been demonstrated that:

[0566] 1. Smaller genetic cassettes exhibit increased localization of expression following subcutaneous administration;

[0567] 2. Increased localization is associated with improved safety and tolerability; and

[0568] 3. Inclusion of the disclosed regulatory and poly adenylation sequences enhances expression without altering biodistribution or localization.

[0569] Accordingly, provides herein are gene therapy constructs that can achieve:

[0570] • high expression potency,

[0571] • favorable localization, and

[0572] • maintained safety profile, thereby overcoming multiple limitations of conventional gene therapy approaches.

[0573] All constructs were otherwise identical, comprising the same promoter, coding sequence, backbone, and baseline polyadenylation sequence unless otherwise specified. Localization was quantified as the ratio of signal intensity within a defined region of interest (ROI) at the injection site relative to total whole-body signal.

[0574] EMBODIMENTS OF THE INVENTION

[0575] #15259787vl1. Therapeutic gene therapy formulations for the treatment of human or veterinary pathologies comprised of:

[0576] a. an adipocyte targeting or subcutaneously localizing nucleic acid delivery vector, b. intended for predominantly subcutaneous administration of DNA,

[0577] c. for production of secreted therapeutic proteins or peptides,

[0578] d. with the goal of mediating distal or systemic therapeutic effect,

[0579] e. which contain at least one subcutaneous-cell-type-specific enhancer sequence or motif selected from a class of pA and optionally one subcutaneous-cell-type specific enhancer sequence or motif selected from a class or Reg positioned downstream of the therapeutic transgene with optimal spacer sequences.

[0580] 2. Therapeutic proteins or peptides in Claim 1, which are derived from a class of incretins.

[0581] 3. Therapeutic proteins or peptides in Claim 1, which are derived from a class of antibodies.

[0582] 4. Therapeutic proteins or peptides in Claim 1, which are derived from a class of human secreted proteins.

[0583] 5. Therapeutic proteins or peptides in Claim 1, which are derived from a class of antibody fragments.

[0584] 6. Therapeutic proteins or peptides in Claim 1, which are derived from a class of fusion proteins.

[0585] 7. Therapeutic protein in Claim 1 , which is a fibroblast growth factor family protein.

[0586] 8. Therapeutic protein in Claim 1 , which is a transforming growth factor-beta (TGF-0) family protein.

[0587] 9. Therapeutic protein in Claim 1 , which is a tumor necrosis factor (TNF) family protein. 10. Therapeutic protein in Claim 1, which is an interleukin family protein.

[0588] 11. Therapeutic protein in Claim 1, which is an interleukin receptor antagonist family protein.

[0589] 12. Therapeutic protein in Claim 1, which is an interferon family protein.

[0590] 13. Therapeutic protein in Claim 1, which is an interferon receptor antagonist family protein.

[0591] 14. Therapeutic protein in Claim 1, which is a colony-stimulating factor (CSF) family protein.

[0592] 15. Therapeutic protein in Claim 1, which is a chemokine family protein.

[0593] 16. Therapeutic protein in Claim 1, which is a vascular endothelial growth factor (VEGF) family protein.

[0594] 17. Therapeutic protein in Claim 1, which is an epidermal growth factor (EGF) family protein.

[0595] #15259787vl18. Therapeutic protein in Claim 1, which is a hepatocyte growth factor (HGF) family protein.

[0596] 19. Therapeutic protein in Claim 1, which is a platelet-derived growth factor (PDGF) family protein.

[0597] 20. Therapeutic protein in Claim 1 , which is an insulin-like growth factor (IGF) family protein.

[0598] 21. Therapeutic protein in Claim 1, which is a bone morphogenetic protein (BMP) family protein.

[0599] 22. Therapeutic protein in Claim 1, which is a glial cell line-derived neurotrophic factor (GDNF) family protein,

[0600] 23. Therapeutic protein in Claim 1, which is a neurotrophin family protein.

[0601] 24. Therapeutic protein in Claim 1, which is a growth differentiation factor (GDF) family protein.

[0602] 25. Therapeutic protein in Claim 1, which is a Wnt family protein.

[0603] 26. Therapeutic protein in Claim 1, which is a hedgehog family protein.

[0604] 27. Therapeutic protein in Claim 1, which is a transforming growth factor-alpha (TGF-a) family protein.

[0605] 28. Therapeutic protein in Claim 1, which is a resistin-like molecule (RELM) family protein.

[0606] 29. Therapeutic protein in Claim 1, which is an angiopoietin family protein.

[0607] 30. Therapeutic protein in Claim 1, which is a galectin family protein.

[0608] 31. Therapeutic protein in Claim 1, which is a secreted frizzled- related protein (sFRP) family protein.

[0609] 32. Therapeutic protein in Claim 1, which is a cystatin family protein.

[0610] 33. Therapeutic protein in Claim 1, which is a serpin family protein.

[0611] 34. Therapeutic protein in Claim 1, which is a cytokine.

[0612] 35. Therapeutic protein in Claim 1, which is a cytokine receptor antagonist.

[0613] 36. Therapeutic protein in Claim 1, which is a defensin family protein.

[0614] 37. Therapeutic protein in Claim 1, which is a cathelicidin family protein.

[0615] 38. Therapeutic protein in Claim 1, which is a lectin family protein.

[0616] 39. Therapeutic protein in Claim 1, which is a prolactin / growth hormone family protein. 40. Therapeutic peptide in Claim 1, which is a gastric inhibitor peptide or derivative.

[0617] 41. Therapeutic peptide in Claim 1, which is a GLP-1 or derivative.

[0618] 42. Therapeutic peptide in Claim 1, which is a glucagon or derivative.

[0619] #15259787vl43. Therapeutic peptide in Claim 1, which is an amylin or derivative.

[0620] 44. Therapeutic protein in Claim 1, which is a protein fused to an albumin peptide.

[0621] 45. Therapeutic protein in Claim 1, which is a protein fused to an Fc-binding peptide. 46. Therapeutic protein in Claim 1, which is a protein fused to an Fc-fragment.

[0622] 47. Therapeutic protein in Claim 1, which is a protein fused to a globulin binding peptide.

[0623] 48. DNA in Claim 1, which is circular double stranded DNA.

[0624] 49. DNA in Claim 1, which is linear double stranded DNA.

[0625] 50. DNA in Claim 1, which is circular single stranded DNA.

[0626] 51. DNA in Claim 1, which is linear single stranded DNA.

[0627] 52. DNA in Claim 1, which is covalently closed DNA.

[0628] 53. DNA in Claim 1, which is chemically modified DNA.

[0629] 54. DNA in Claim 1, which is a DNA / RNA hybrid.

[0630] 55. DNA in Claim 1, which is chemically conjugated to peptides or small molecules. 56. Vectors in Claim 1, which are non- viral vectors.

[0631] 57. Vectors in Claim 1, which are lipid nanoparticles.

[0632] 58. Vectors in Claim 1, which are liposomes.

[0633] 59. Vectors in Claim 1, which are lipid micelles.

[0634] 60. Vectors in Claim 1, which are carbon nanotubes.

[0635] 61. Vectors in Claim 1, which are nano emulsion droplets.

[0636] 62. Vectors in Claim 1, which are lipid bilayer sheets.

[0637] 63. Vectors in Claim 1, which are poly electrolytic complexes.

[0638] 64. Vectors in Claim 1, which are polymeric nanoparticles.

[0639] 65. Vectors in Claim 1, which are dendrimers.

[0640] 66. Vectors in Claim 1, which are polymers.

[0641] 67. Vectors in Claim 1, which are biopolymers.

[0642] 68. Vectors in Claim 1, which are bioresorbable polymers.

[0643] 69. Vectors in Claim 1, which are polyethyleneimine complexes.

[0644] 70. Vectors in Claim 1, which are solid lipid nanoparticles.

[0645] 71. Vectors in Claim 1, which are exosomes.

[0646] 72. Vectors in Claim 1, which are micelles.

[0647] 73. Vectors in Claim 1, which are cell-penetrating peptides.

[0648] #15259787vl74. Vectors in Claim 1, which are cationic emulsions.

[0649] 75. Vectors in Claim 1, which are calcium phosphate nanoparticles.

[0650] 76. Vectors in Claim 1, which are silica nanoparticles.

[0651] 77. Vectors in Claim 1, which are metallic nanoparticles.

[0652] 78. Vectors in Claim 1, which are ceramic nanoparticles.

[0653] 79. Vectors in Claim 1, which are DNA nanostructures.

[0654] 80. Vectors in Claim 1, which are naked plasmid DNA formulations.

[0655] 81. Vectors in Claim 1, which are non-viral vectors functionalized with peptides, polymers, monosaccharides, polysaccharides, oligosaccharides, antibodies, fragments, or proteins.

[0656] 82. Vectors in Claim 1 , which are combinations of one or more non-viral vector gene therapies.

[0657] 83. Vector in Claim 1, which is a viral vector or combination of viral vectors.

[0658] 84. Vector in Claim 1, wherein the vector is adenovirus.

[0659] 85. Vector in Claim 1, wherein the vector is lenti virus.

[0660] 86. Vector in Claim 1, wherein the vector is retrovirus.

[0661] 87. Vector in Claim 1, wherein the vector is herpes simplex virus.

[0662] 88. Vector in Claim 1, wherein the vector is vaccinia virus or Modified Vaccinia Ankara (MVA).

[0663] 89. Vector in Claim 1, wherein the vector is cytomegalovirus.

[0664] 90. Vector in Claim 1, wherein the vector is comprised of one or more of an Alphacoronavirus, Alphaherpesvirus, Alpharetrovirus, Alphavirus, Anellovirus, Astrovirus, Avulavirus, Betacoronavirus, Betaherpesvirus, Betaretrovirus, Bornavirus, Bunyavirus, Calicivirus, Circovirus, Coxsackievirus, Deltacoronavirus, Deltaretrovirus, Dengue virus, Ebolavirus, Enterovirus, Filovirus, Flavivirus, Gammacoronavirus, Gammaherpesvirus, Hantavirus, Hepacivirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Human immunodeficiency virus (HIV), Human papillomavirus (HPV), Influenza virus, Lyssavirus, Marburgvirus, Measles virus, Metapneumovirus, Mumps virus, Norovirus, Orthohantavirus, Orthomyxovirus, Parainfluenza virus, Parechovirus, Picornavirus, Poliovirus, Polyomavirus, Rabies virus, Reovirus, Respiratory syncytial virus (RSV), Rhinovirus, Rotavirus, Rubivirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Simian foamy virus, Tenuivirus, Togavirus, Varicella-zoster virus, Variola virus (Smallpox virus), Vesiculovirus, West Nile virus, Yellow fever virus,

[0665] #15259787vlZika virus, and a nucleic acid sequence encoding a therapeutic transgene, wherein the composition is configured for subcutaneous administration.

[0666] 91. Administration in Claim 1, which is a subcutaneous injection.

[0667] 92. Administration in Claim 1 , which is at least in part an intravenous injection of a formulation that targets adipocytes.

[0668] 93. Administration in Claim 1, which is an intravenous injection of a formulation that targets subcutaneous adipocytes.

[0669] 94. Administration in Claim 1, which is a subcutaneous infusion.

[0670] 95. Administration in Claim 1, which is performed via an autoinjector, patch injector, pen injector, syringe, patch, jet injector, or via microneedles.

[0671] 96. Specific enhancer sequence in Claim 1, which is derived from the Reg class sequences.

[0672] 97. Specific enhancer sequence in Claim 1, which is derived from the pA class sequences. 98. Specific enhancer sequence in Claim 1, which is a combination of sequences derived from the Reg and pA class sequences.

[0673] 99. Specific enhancer motif in Claim 1, which is the sequence with Reg 1 (SEQ ID NO: 59) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0674] 100. Specific enhancer motif in Claim 1 , which is the sequence with Reg 2 (SEQ ID NO:

[0675] 53) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0676] 101. Specific enhancer motif in Claim 1 , which is the sequence with Reg 3 (SEQ ID NO:

[0677] 52) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0678] 102. Specific enhancer motif in Claim 1 , which is the sequence with Reg 4 (SEQ ID NO:

[0679] 60) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0680] 103. Specific enhancer motif in Claim 1, which is the sequence with Reg 5 (SEQ ID NO:

[0681] 54) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0682] 104. Specific enhancer motif in Claim 1 , which is the sequence with Reg 6 (SEQ ID NO:

[0683] 55) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0684] 105. Specific enhancer motif in Claim 1, which is the sequence with Reg 7 (SEQ ID NO:

[0685] 56) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0686] 106. Specific enhancer motif in Claim 1 , which is the sequence with Reg 8 (SEQ ID NO:

[0687] 57) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0688] #15259787vl107. Specific enhancer motif in Claim 1 , which is the sequence with Reg 9 (SEQ ID NO: 58) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0689] 108. Specific enhancer motif in Claim 1, which is the sequence with Reg 10 (SEQ ID NO: 1) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0690] 109. Specific enhancer motif in Claim 1, which is the sequence from a set of sequences with Reg 10 to Reg 110 (SEQ ID NOs: 1-50) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0691] 110. Specific enhancer motif in Claim 1, which is the sequence that shares >50% coverage and >72% identity to Reg 1 (SEQ ID NO: 59) positioned 0-12 nt downstream of a stop codon.

[0692] 111. Specific sequence in Claim 1 from a class of pA sequences labeled pA 1 (SEQ ID NO: 122) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0693] 112. Specific sequence in Claim 1 from a class of pA sequences labelled pA 1 (SEQ ID NO: 122) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0694] 113. Specific sequence in Claim 1 from a class of pA sequences labelled pA 2 (SEQ ID NO: 121) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0695] 114. Specific sequence in Claim 1 from a class of pA sequences labelled pA 2 (SEQ ID NO: 121) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0696] 115. Specific sequence in Claim 1 from a class of pA sequences labelled pA 1 (SEQ ID NO: 122) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0697] 116. Specific sequence in Claim 1 from a class of pA sequences labelled pA 3 (SEQ ID NO: 118) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0698] 117. Specific sequence in Claim 1 from a class of pA sequences labelled pA 3 (SEQ ID NO: 118) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0699] 118. Specific sequence in Claim 1 from a class of pA sequences labelled pA 4 (SEQ ID NO: 95) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0700] #15259787vl119. Specific sequence in Claim 1 from a class of pA sequences labelled pA 4 (SEQ ID NO: 95) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0701] 120. Specific sequence in Claim 1 from a class of pA sequences labelled pA 5 (SEQ ID NO: 96) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0702] 121. Specific sequence in Claim 1 from a class of pA sequences labelled pA 5 (SEQ ID NO: 96) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0703] 122. Specific sequence in Claim 1 from a class of pA sequences labelled pA 6 positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0704] 123. Specific sequence in Claim 1 from a class of pA sequences labelled pA 6 positioned 0-12 nucleotides downstream of any Reg class sequence.

[0705] 124. Specific sequence in Claim 1 from a class of pA sequences labelled pA 7 (SEQ ID NO: 98) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0706] 125. Specific sequence in Claim 1 from a class of pA sequences labelled pA 7 (SEQ ID NO: 98) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0707] 126. Specific sequence in Claim 1 from a class of pA sequences labelled pA 8 (SEQ ID NO: 99) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0708] 127. Specific sequence in Claim 1 from a class of pA sequences labelled pA 8 (SEQ ID NO: 99) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0709] 128. Specific sequence in Claim 1 from a class of pA sequences labelled pA 9 (SEQ ID NO: 100) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0710] 129. Specific sequence in Claim 1 from a class of pA sequences labelled pA 9 (SEQ ID NO: 100) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0711] 130. Specific sequence in Claim 1 from a class of pA sequences from the set labelled pA 10 to pA 53 (SEQ ID NOs: 61-94, 101, 121) positioned 0-12 nucleotides downstream of the stop codon of the therapeutic transgene.

[0712] #15259787vl131. Specific sequence in Claim 1 from a class of pA sequences from the set labelled pA 10 to pA 53 (SEQ ID NOs: 61-94, 101, 121) positioned 0-12 nucleotides downstream of any Reg class sequence.

[0713] 132. Specific sequence in Claim 1, which is a sequence with the Combination A (SEQ ID NO: 119) positioned starting 0-12 nt after a stop codon.

[0714] 133. Specific sequence in Claim 1, which is a sequence with the Combination B (SEQ ID NO: 120) positioned starting 0-12 nt after a stop codon.

[0715] 134. Specific sequence in Claim 1, which is a sequence with the Combination C (SEQ ID NO: 102) positioned starting 0-12 nt after a stop codon.

[0716] 135. Specific sequence in Claim 1, which is a sequence with the Combination D (SEQ ID NO: 103) positioned starting 0-12 nt after a stop codon.

[0717] 136. Specific sequence in Claim 1, which is a sequence with the Combination E (SEQ ID NO: 104) positioned starting 0-12 nt after a stop codon.

[0718] 137. Specific sequence in Claim 1, which is a sequence with the Combination F (SEQ ID NO: 105) positioned starting 0-12 nt after a stop codon.

[0719] 138. Specific sequence in Claim 1, which is a sequence with the Combination G (SEQ ID NO: 105) positioned starting 0-12 nt after a stop codon.

[0720] 139. Specific sequence in Claim 1, which is a sequence with the Full Combination A (SEQ ID NO: 119) positioned starting 0-12 nt after a stop codon.

[0721] 140. Specific sequence in Claim 1, which is a sequence with the Full Combination B (SEQ ID NO: 106) positioned starting 0-12 nt after a stop codon.

[0722] 141. Specific sequence in Claim 1, which is a sequence with the Full Combination C (SEQ ID NO: 107) positioned starting 0-12 nt after a stop codon.

[0723] 142. Specific sequence in Claim 1, which is a sequence with the Full Combination D (SEQ ID NO: 108) positioned starting 0-12 nt after a stop codon.

[0724] 143. Specific sequence in Claim 1, which is a sequence with the Full Combination E (SEQ ID NO: 109) positioned starting 0-12 nt after a stop codon.

[0725] 144. Specific sequence in Claim 1, which is a sequence with the Full Combination F (SEQ ID NO: 110) positioned starting 0-12 nt after a stop codon.

[0726] 145. Specific sequence in Claim 1, which is a sequence with the Full Combination G (SEQ ID NO: 111) positioned starting 0-12 nt after a stop codon.

[0727] #15259787vl146. Specific sequence in Claim 1, which is a sequence with the Full Combination H (SEQ ID NO: 112) positioned starting 0-12 nt after a stop codon.

[0728] 147. Specific sequence in Claim 1, which is a sequence with the Full Combination I (SEQ ID NO: 113) positioned starting 0-12 nt after a stop codon.

[0729] 148. Specific sequence in Claim 1, which is a sequence with the Full Combination J (SEQ ID NO: 114) positioned starting 0-12 nt after a stop codon.

[0730] 149. Specific sequence in Claim 1, which is a sequence with the Full Combination K (SEQ ID NO: 115) positioned starting 0-12 nt after a stop codon.

[0731] 150. Specific sequence in Claim 1, which is a sequence with the Full Combination L (SEQ ID NO: 116) positioned starting 0-12 nt after a stop codon.

[0732] 151. Specific sequence in Claim 1, which is a sequence with the Full Combination M (SEQ ID NO: 96) positioned starting 0-12 nt after a stop codon.

[0733] 152. Specific enhancer sequence in Claim 1, which is derived from a natural parent sequence via the exclusion of the motif defined in SEQ ID NO: 51.

[0734] 153. Pathologies in Claim 1, which are one or more of Hypertension, coronary artery disease, heart failure, stroke, atrial fibrillation, peripheral artery disease, type 2 diabetes mellitus, type 1 diabetes, obesity, hyperlipidemia, metabolic syndrome, hypothyroidism, polycystic ovary syndrome, chronic obstructive pulmonary disease, asthma, pneumonia, pulmonary fibrosis, lung cancer, Alzheimer’s disease, Parkinson’s disease, epilepsy, migraine, multiple sclerosis, depression, anxiety disorders, bipolar disorder, schizophrenia, substance use disorders, gastroesophageal reflux disease, irritable bowel syndrome, inflammatory bowel disease, hepatitis B, hepatitis C, liver cirrhosis, breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, leukemias, lymphomas, osteoarthritis, rheumatoid arthritis, osteoporosis, low back pain, HIV / AIDS, tuberculosis, malaria, influenza, COVID- 19, human papillomavirus infection, hepatitis A, hepatitis D, hepatitis E, acne vulgaris, psoriasis, atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, melanoma, chronic kidney disease, urinary tract infections, nephrolithiasis, benign prostatic hyperplasia, infertility, endometriosis, uterine fibroids, erectile dysfunction or related diseases.

[0735] 154. Pathologies in Claim 1, which are derived from a class of autoimmune disorders, monogenic conditions, reproductive disorders, renal & urological diseases, dermatologic

[0736] #15259787vlconditions, infectious diseases, musculoskeletal disorders, oncologies, gastrointestinal disorders, psychiatric & behavioral conditions, neurological disorders, respiratory diseases, metabolic & endocrine disorders, cardiovascular diseases or related pathologies.

[0737] 155. Spacer sequences in Claim 1, which follow the therapeutic transgene stop codon and are A / C / T / G or A / C / T / G followed by A / C / T / G or A / C / T / G followed by A / C / T / G followed by A / C / T / G.

[0738] 156. Spacer sequences in Claim 1, which follow the therapeutic transgene stop codon and are DNA sequences of 0-12 nucleotides.

[0739] 157. Spacer sequences in Claim 1, which follow the therapeutic transgene stop codon and are TAA, TAG, or TGA.

[0740] 158. Spacer sequences in Claim 1, which follow the Reg element and are A / C / T / G or A / C / T / G followed by A / C / T / G or A / C / T / G followed by A / C / T / G followed by A / C / T / G.

[0741] 159. Spacer sequences in Claim 1, which follow the Reg element and are CTG, or CTGCAG, CTGCAGACA, or CTGCAGACATGA (SEQ ID NO: 117).

[0742] 160. Sequence in Claim 1, from a class of pA sequences which is TAAGATACATTGATGAGTTTGGACCA (SEQ ID NO: 123) and positioned starting 0- 12 nucleotides following the stop codon.

[0743] 161. Sequence in Claim 1, from a class of pA sequences which is TTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAA (SEQ ID NO: 124) and positioned starting 70 to 82 nucleotides following the stop codon

[0744] 162. Sequence in Claim 1, from a class of pA sequences which is [A / G]G[T / G]TG]C / G]CA[G / T]CC[A / C]T[C / G]TG (SEQ ID NO: 125) and positioned starting 0 to 23 nucleotides following the stop codon

[0745] 163. Sequence in Claim 1, from a class of pA sequences which is CCCCTCCCC[C / A]GTGCCT (SEQ ID NO: 126) and positioned starting 17 to 25 or 35 to 47 nucleotides following the stop codon.

[0746] #15259787vl

Claims

CLAIMSWhat is claimed is:

1. A gene therapy construct comprising:(a) a nucleic acid encoding a therapeutic protein or peptide;(b) at least one regulatory sequence operably linked to the nucleic acid; and(c) at least one polyadenylation sequence operably linked to the regulatory sequence, wherein the polyadenylation sequence increases expression in subcutaneous tissue relative to a reference polyadenylation sequence,wherein the gene therapy construct comprises a therapeutic genetic cassette having a total length of between 2208 nucleotides and 7356 nucleotides,wherein the gene therapy construct is configured for subcutaneous administration using a non-viral delivery vector, andwherein inclusion of the regulatory sequence and the polyadenylation sequence results in an increase in expression of the therapeutic protein or peptide in vivo following subcutaneous administration relative to an otherwise identical construct lacking the regulatory sequence, wherein the increase in expression is greater than that achieved by inclusion of either the regulatory sequence alone or the polyadenylation sequence alone,and wherein the increase in expression exceeds any reduction in expression attributable to an increase in construct size resulting from inclusion of the regulatory sequence and the poly adenylation sequence.

2. A method of treating a subject in need thereof, comprising:subcutaneously administering to the subject the gene therapy construct of claim 1, wherein the construct expresses a therapeutically effective amount of the therapeutic protein or peptide.#15259787vl3. Use of a regulatory sequence and a polyadenylation sequence in combination to increase expression of a nucleic acid encoding a therapeutic protein or peptide following subcutaneous administration of a non-viral gene therapy construct, wherein the increase in expression exceeds any reduction attributable to an increase in construct size.

4. The gene therapy construct of claim 1, wherein the non-viral delivery vector comprises a lipid nanoparticle.

5. The gene therapy construct of claim 1, wherein the construct is delivered without a viral capsid.

6. The gene therapy construct of claim 1, wherein expression occurs in subcutaneous tissue.

7. The gene therapy construct of claim 6, wherein expression occurs in adipocytes.

8. The gene therapy construct of claim 1, wherein the regulatory sequence is positioned within 0 to 50 nucleotides downstream of a stop codon of the nucleic acid.

9. The gene therapy construct of claim 8, wherein the regulatory sequence is positioned within 0 to 12 nucleotides downstream of the stop codon.

10. The gene therapy construct of claim 1, wherein the regulatory sequence is positioned between 300 and 500 nucleotides downstream of a stop codon.

11. The gene therapy construct of claim 10, wherein the regulatory sequence is positioned between 350 and 420 nucleotides downstream of the stop codon.

12. The gene therapy construct of claim 1, further comprising a spacer sequence between the nucleic acid and the regulatory sequence.

13. The gene therapy construct of claim 12, wherein the spacer sequence comprises 0 to 12 nucleotides.

14. The gene therapy construct of claim 13, wherein the spacer comprises 1 to 3 nucleotides.

15. The gene therapy construct of claim 1, wherein the increase in expression is at least 1.5-fold relative to the construct lacking the regulatory sequence.#15259787vl16. The gene therapy construct of claim 15, wherein the increase in expression is at least 2-fold.

17. The gene therapy construct of claim 1, wherein the increase in expression is observed across constructs having lengths spanning 2208 to 7356 nucleotides.

18. The gene therapy construct of claim 1, wherein the regulatory sequence comprises a nucleic acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: Reg 1-Reg 110.

19. The gene therapy construct of claim 18, wherein the sequence has at least 88% identity.

20. The gene therapy construct of claim 1, wherein the poly adenylation sequence comprises a sequence having at least 80% identity to any one of SEQ ID NOs: pA 1-pA 53.

21. The gene therapy construct of claim 20, wherein the sequence has at least 88% identity.

22. The gene therapy construct of claim 18, wherein the regulatory sequence comprises a conserved motif derived from alignment of SEQ ID NOs: Reg 1-Reg 3.

23. The gene therapy construct of claim 20, wherein the polyadenylation sequence comprises a consensus motif associated with increased expression in subcutaneous tissue.

24. The gene therapy construct of claim 1, wherein the regulatory sequence comprises SEQ ID NO: Reg 1 and the polyadenylation sequence comprises SEQ ID NO: pA 4.

25. The gene therapy construct of claim 1, wherein the regulatory sequence comprises SEQ ID NO: Reg 1 and the polyadenylation sequence comprises SEQ ID NO: pA 1.

26. The gene therapy construct of claim 1, wherein the regulatory sequence comprises SEQ ID NO: Reg 3 and the polyadenylation sequence comprises SEQ ID NO: pA 4.

27. The gene therapy construct of claim 1, wherein the construct does not comprise a sequence having at least 80% identity to SEQ ID NO: EE3.

28. The gene therapy construct of claim 1, wherein the therapeutic protein or peptide is a secreted protein.#15259787vl29. The gene therapy construct of claim 28, wherein the protein is a peptide hormone.

30. The gene therapy construct of claim 28, wherein the protein is an antibody or antibody fragment.

31. A gene therapy construct comprising :• a nucleic acid encoding a therapeutic protein• a regulatory sequence selected from SEQ ID NOs: Reg 1-Reg 110• a polyadenylation sequence selected from SEQ ID NOs: pA 1-pA 53wherein the construct increases expression following subcutaneous administration relative to a construct lacking the regulatory sequence.#15259787vl